Nutra Pharma (NPHC) 10-Q 5 Aug 21 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 05, 2021
Cover [Abstract]
Entity Registrant Name	NUTRA PHARMA CORP
Entity Central Index Key	0001119643
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,267,619,714
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 57,870
Accounts receivable	34,060	32,479
Inventory, current portion	6,376	8,177
Prepaid expenses and other current assets	15,265	17,150
Total current assets	113,571	57,806
Inventory, less current portion	65,568	52,183
Property and equipment, net	5,339	6,763
Operating lease right-of-use assets	168,234	207,530
Security deposit	8,803	15,550
Total assets	361,515	339,832
Current liabilities:
Accounts payable	543,399	583,226
Accrued expenses	682,355	612,547
Accrued payroll due to officers	1,338,693	1,249,393
Accrued interest to related parties	169,190	159,555
Due to officer	193,216	122,812
Derivative liabilities	1,337,115	835,868
Other debt, net of discount, current portion	5,826,693	7,352,954
Operating lease obligations, current portion	77,945	73,278
Total current liabilities	10,168,606	10,989,633
Convertible note, less current portion	306,462	907,912
SBA notes payable	214,795
Operating lease obligations, less current portion	103,432	143,322
Total liabilities	10,793,295	12,040,867
Commitments and Contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at June 30, 2020 and December 31, 2019	3,000	3,000
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 6,627,746,111 and 5,876,746,111 shares issued and outstanding at June 30, 2020 and December 31, 2019	6,627,746	5,876,746
Additional paid-in capital	50,125,203	50,283,503
Accumulated deficit	(67,187,729)	(67,864,284)
Total stockholders' deficit	(10,431,780)	(11,701,035)
Total liabilities and stockholders' deficit	$ 361,515	$ 339,832

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	8,000,000,000	8,000,000,000
Common stock, shares issued	6,627,746,111	5,876,746,111
Common stock, shares outstanding	6,627,746,111	5,876,746,111
Series A Preferred Stock [Member]
Preferred stock, shares issued	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net sales		$ 6,240	$ 10,215	$ 23,356	$ 51,537
Cost of sales		(3,685)	(3,774)	(8,964)	(19,399)
Gross profit		2,555	6,441	14,392	32,138
Operating expenses:
Selling, general and administrative - including stock based compensation of $1,000 and $26,500 for the three months ended June 30, 2020 and 2019, and $8,500 and $56,500 for the six months ended June 30, 2020 and 2019, respectively		235,427	334,287	476,868	608,922
Bad debt recovery - related party		(31,000)		(70,500)
Total operating expenses		204,427	334,287	406,368	608,922
Loss from operations		(201,872)	(327,846)	(391,976)	(576,784)
Other income (expenses)
Rental income		3,000		6,000
Other income		5,000		5,000
Interest expense		(78,238)	(59,832)	(147,111)	(134,977)
Interest expense to related parties		(4,914)	(4,368)	(9,635)	(8,564)
Change in fair value of convertible notes and derivatives		(1,226,465)	(1,275,111)	1,316,477	(1,404,528)
Stock issued for loan modification		(3,000)	(1,050)	(80,200)	(1,050)
Gain (loss) on settlement of debt and accrued expense, net				(22,000)	57,253
Total other income (expenses)		(1,304,617)	(1,340,361)	1,068,531	(1,491,866)
Income (loss) before income taxes		(1,506,489)	(1,668,207)	676,555	(2,068,650)
Provision for income taxes
Net income (loss)		$ (1,506,489)	$ (1,668,207)	$ 676,555	$ (2,068,650)
Net income (loss) per share - basic and diluted		$ 0	$ 0	$ 0	$ 0
Weighted average number of shares outstanding during the period - basic		6,623,845,012	4,612,987,869	6,448,086,770	4,336,212,961
Weighted average number of shares outstanding during the period - diluted	[1]	6,623,845,012	4,612,987,869	12,971,980,061	4,336,212,961
[1]	Includes potential common shares that are in excess of authorized shares.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Stock based compensation	$ 1,000	$ 26,500	$ 8,500	$ 56,500

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 3,000	$ 4,046,746	$ 51,286,503	$ (61,272,842)	$ (5,936,593)
Balance, shares at Dec. 31, 2018	3,000,000	4,046,746,110
Issuance of common stock in exchange for services to consultants		$ 135,000	(105,000)		30,000
Issuance of common stock in exchange for services to consultants, shares		135,000,000
Common stock issued for debt modification and penalty		$ 3,500	(2,450)		1,050
Common stock issued for debt modification and penalty, shares		3,500,000
Common stock issued for conversion of debt		$ 750,000	(475,000)		275,000
Common stock issued for conversion of debt, shares		750,000,000
Common stock issued with Debt-Debt discount		$ 22,000	(15,512)		6,488
Common stock issued with Debt-Debt discount, shares		22,000,001
Common stock issued for settlement of debt		$ 81,000	(48,600)		32,400
Common stock issued for settlement of debt, shares		81,000,000
Warrants issued with Debt-Debt discount			8,147		8,147
Net income loss				(2,068,650)	(2,068,650)
Balance at Jun. 30, 2019	$ 3,000	$ 5,038,246	50,648,088	(63,341,492)	(7,652,158)
Balance, shares at Jun. 30, 2019	3,000,000	5,038,246,111
Balance at Mar. 31, 2019	$ 3,000	$ 4,127,746	51,246,050	(61,673,285)	(6,296,489)
Balance, shares at Mar. 31, 2019	3,000,000	4,127,746,110
Issuance of common stock in exchange for services to consultants		$ 135,000	(105,000)		30,000
Issuance of common stock in exchange for services to consultants, shares		135,000,000
Common stock issued for debt modification and penalty		$ 3,500	(2,450)		1,050
Common stock issued for debt modification and penalty, shares		3,500,000
Common stock issued for conversion of debt		$ 750,000	(475,000)		275,000
Common stock issued for conversion of debt, shares		750,000,000
Common stock issued with Debt-Debt discount		$ 22,000	(15,512)		6,488
Common stock issued with Debt-Debt discount, shares		22,000,001
Net income loss				(1,668,207)	(1,668,207)
Balance at Jun. 30, 2019	$ 3,000	$ 5,038,246	50,648,088	(63,341,492)	(7,652,158)
Balance, shares at Jun. 30, 2019	3,000,000	5,038,246,111
Balance at Dec. 31, 2019	$ 3,000	$ 5,876,746	50,283,503	(67,864,284)	(11,701,035)
Balance, shares at Dec. 31, 2019	3,000,000	5,876,746,111
Common stock issued for debt modification and penalty		$ 126,000	(45,800)		80,200
Common stock issued for debt modification and penalty, shares		126,000,000
Common stock issued for conversion of debt		$ 500,000	(75,000)		425,000
Common stock issued for conversion of debt, shares		500,000,000
Common stock issued for settlement of debt		$ 125,000	(37,500)		87,500
Common stock issued for settlement of debt, shares		125,000,000
Net income loss				676,555	676,555
Balance at Jun. 30, 2020	$ 3,000	$ 6,627,746	50,125,203	(67,187,729)	(10,431,780)
Balance, shares at Jun. 30, 2020	3,000,000	6,627,746,111
Balance at Mar. 31, 2020	$ 3,000	$ 6,622,746	50,127,203	(65,681,240)	(8,928,291)
Balance, shares at Mar. 31, 2020	3,000,000	6,622,746,111
Common stock issued for debt modification and penalty		$ 5,000	(2,000)		3,000
Common stock issued for debt modification and penalty, shares		5,000,000
Net income loss				(1,506,489)	(1,506,489)
Balance at Jun. 30, 2020	$ 3,000	$ 6,627,746	$ 50,125,203	$ (67,187,729)	$ (10,431,780)
Balance, shares at Jun. 30, 2020	3,000,000	6,627,746,111

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ (1,506,489)	$ (1,668,207)	$ 676,555	$ (2,068,650)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Bad debt expense				31,789
Bad debt recovery - related party	(31,000)		(70,500)
Accrued interest expense for amount due to officer			3,654	3,536
Loss (gain) on settlement of debt and accrued expense			22,000	(57,253)
Depreciation	712	1,105	1,424	2,210
Stock-based compensation	1,000	26,500	8,500	56,500
Stock-based loan modification cost			80,200	1,050
Change in fair value of convertible notes and derivatives	1,226,465	1,275,111	(1,316,477)	1,404,528
Amortization of loan discount			58,829	62,078
Amortization of operating lease right-of-use assets			39,296	29,288
Changes in operating assets and liabilities:
Increase in accounts receivable			(1,581)	(13,858)
Increase in inventory			(11,584)	(1,226)
Decrease (increase) in prepaid expenses and other current assets			132	(7,848)
(Decrease) increase in accounts payable			(39,827)	77,868
Increase in accrued expenses			97,458	115,811
Increase in accrued payroll due to officers			89,300	102,900
Increase in accrued interest to related parties			9,635	8,564
Decrease in operating lease obligations			(35,223)	(30,990)
Net cash used in operating activities			(388,209)	(283,703)
Cash flows from financing activities:
Loans from officer			152,700	4,100
Repayment of officer loans			(15,450)	(61,715)
Repayments of notes payable-related party			(14,400)
Proceeds from convertible notes			111,875	484,879
Repayment of convertible notes				(10,000)
Advances from an unrelated third party			50,000
Repayments of other notes payable			(53,441)	(19,848)
Proceeds from SBA notes payable			214,795
Net cash provided by financing activities			446,079	397,416
Net increase in cash			57,870	113,713
Cash - beginning of period
Cash - end of period	$ 57,870	$ 113,713	57,870	113,713
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes
Non Cash Financing and Investing:
Stock issued in settlement of notes, accounts payable, and accrued expenses			87,500	32,400
Shares issued for conversion of debt			425,000	275,000
Warrants issued with Debt-Debt discount				14,635
Right-of-use asset due to adoption of ASC 842				281,175
Operating lease liabilities due to adoption of ASC 842				281,175
Reclassification of accrued interest to debt			$ 12,150

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $67,187,729 at June 30, 2020. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $10,055,035 and a stockholders’ deficit of $10,431,780 at June 30, 2020. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $64,895. We used the proceeds primarily for payroll costs. We expect forgiveness of this loan under the current terms of requirement by the SBA. During April and June 2020, we obtained a loan in the amount of $150,000 from SBA under its Economic Injury Disaster Loan assistance program. We used the proceeds primarily for rent, payroll, utilities, accounting and legal expenses (See Note 6). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No allowance for doubtful account is deemed to be required at June 30, 2020 and December 31, 2019. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at June 30, 2020 and December 31, 2019, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $0 and $23,948, respectively. At both June 30, 2020 and December 31, 2019, the total valuation allowance for prepaid venom was $224,859. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended June 30, 2020, there was no customer accounted for more than 10% of the total revenues. For the three months ended June 30, 2019, there was one customer that accounted for 27% of the total revenues. For the six months ended June 30, 2020, there was one customer that accounted for 43% of the total revenues. For the six months ended June 30, 2019, there were two customers that accounted for 25% and 49% of the total revenues, respectively. As of June 30, 2020 and December 31, 2019, 100% of the accounts receivable balance are reserves due from two payment processors. Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes The Company recorded no income tax expense for the six months ended June 30, 2020 and 2019 because the estimated annual effective tax rate was zero. As of June 30, 2020, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Basic and diluted numerator: Net income (loss) - basic $ (1,506,489 ) $ (1,668,207 ) $ 676,555 $ (2,068,650 ) Effect of dilutive securities: Change in fair value of convertible notes - - (1,818,618 ) - Interest on convertible debt - - 16,167 - Net loss - diluted $ (1,506,489 ) $ (1,668,207 ) $ (1,125,896 ) $ (2,068,650 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 6,623,845,012 4,612,987,869 6,448,086,770 4,336,212,961 Effect of dilutive securities: Convertible debt - - 6,523,893,291 - Weighted-average common shares outstanding - diluted (1) 6,623,845,012 4,612,987,869 12,971,980,061 4,336,212,961 Net income (loss) per share - basic and diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. As of June 30, 2020 and 2019, the following items were not included in dilutive loss as the effect is anti-dilutive: June 30, 2020 June 30, 2019 Options and warrants 46,500,000 118,500,000 Convertible notes payable at fair value - 7,050,986,979 Convertible notes payable - 1,230,580,833 Total 46,500,000 8,400,067,812 Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at June 30, 2020 and December 31, 2019 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at June 30, 2020 and December 31, 2019: Fair Value Measurements at June 30, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 517 $ - $ - $ 517 Derivative liabilities $ 1,336,598 $ - $ - $ 1,336,598 Convertible notes at fair value $ 3,613,041 $ - $ - $ 3,613,041 Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ - $ 834,457 Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the six months ended June 30, 2020 and the year ended December 31, 2019: Description June 30, 2020 December 31, 2019 Beginning balance $ 1,411 $ 1,468 Total gain included in earnings (1) (894 ) (57 ) Ending balance $ 517 $ 1,411 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.17% to 1.59% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 320%-348% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at June 30, 2020. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at June 30, 2020 and December 31, 2019: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back June 30, 2020 $ 1,088,578 8%-10% 20%-24% N/A $0.00025-$0.00044 50%-60% 3 to 25 Days December 31, 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2020 and the year ended December 31, 2019: Description June 30, 2020 December 31, 2019 Beginning balance $ 5,814,047 $ 1,156,341 Purchases and issuances 19,374 688,274 Day one loss on value of hybrid instrument (1) 24,598 926,109 Loss (gain) from change in fair value (1) (1,842,322 ) 3,423,935 Debt discount 22,344 (22,344 ) Settlement through issuance of common stock - (83,268 ) Conversion to common stock (425,000 ) (275,000 ) Ending balance $ 3,613,041 $ 5,814,047 (1) The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At June 30, 2020 and December 31, 2019, inventories were as follows: June 30, 2020 December 31, 2019 Raw Materials $ 65,568 $ 52,183 Finished Goods 6,376 8,177 Total Inventories 71,944 60,360 Less: Long-term inventory (65,568 ) (52,183 ) Current portion $ 6,376 $ 8,177

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at June 30, 2020 and December 31, 2019: June 30, 2020 December 31, 2019 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (210,694 ) (209,270 ) Property and equipment, net $ 5,339 $ 6,763 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At June 30, 2020, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the six-months ended June 30, 2020 and 2019 was $1,424 and $2,210, respectively, and $712 and $1,105 for the three-months ended June 30, 2020 and 2019, respectively.

Due to_from Officer

Due to/from Officer	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Due to/from Officer	5. DUE TO/FROM OFFICER At June 30, 2020, the balance due to our President and CEO, Rik Deitsch, is $193,216, which is an unsecured demand loan that bears interest at 4%. During the six months ended June 30, 2020, we advanced $15,450 to and collected $152,700 from Mr. Deitsch and the companies owned by him. Additionally, accrued interest on the demand loan was $3,654 and is included in the due to officer account. The Company has fully reserved receivables from companies owned by the Company’s CEO. The reserve was $493,970 and $564,470 as of June 30, 2020 and December 31, 2019, which represents a full valuation allowance for amounts owed by these companies. For the six months ended June 30, 2020 and 2019, we recorded a bad debt recovery of $70,500 and $0, respectively. For the three months ended June 30, 2020 and 2019, we recorded a bad debt recovery of $31,000 and $0, respectively. At December 31, 2019, the balance due to our President and CEO, Rik Deitsch, is $122,812, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2019, we advanced $134,015 to and collected $5,000 from Mr. Deitsch and the companies owned by him. Additionally, accrued interest on the demand loan was $6,330 and is included in the due to officer account.

Debts

Debts	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Debts	6. DEBTS Debts consist of the following at June 30, 2020 and December 31, 2019: June 30, 2020 December 31, 2019 Note payable– Related Party (1) $ - $ 14,400 Notes payable – Unrelated third parties (Net of discount of $9,972 and $8,921, respectively) (2) 1,382,898 1,385,163 Convertible notes payable – Unrelated third parties (Net of discount of $3,084 and $17,370, respectively) (3) 912,216 872,256 Convertible notes payable, at fair value (Net of discount of $0 and $22,344, respectively) (4) 3,613,041 5,814,047 Other advances from an unrelated third party (5) 225,000 175,000 SBA notes payable(6) 214,795 - Ending balances 6,347,950 8,260,866 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (306,462 ) (907,912 ) Less: Long-term portion- SBA notes payable (214,795 ) - Current portion $ 5,826,693 $ 7,352,954 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid the principal balance in full as of December 31, 2016. At June 30, 2020 and December 31, 2019, we owed this director accrued interest of $169,190 and $159,555, respectively. The interest expense for the six-months ended June 30, 2020 and 2019 was $9,635 and $8,564, respectively, and $4,914 and $4,368 for the three-months ended June 30, 2020 and 2019, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. The Note of $14,400 was paid in full in cash during June 2020. In addition, we issued 5,000,000 shares due to the default on repayment of the note. The shares were valued at fair value of $3,000(See Note 7). At June 30, 2020 and December 31, 2019, the principal balance of the loan is $0 and $14,400. (2) At June 30, 2020 and December 31, 2019, the balance of $1,382,898 and $1,385,163 net of discount of $9,972 and $8,921, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 12) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2020 and December 31, 2019, the accrued interest is $4,258 and $3,755, respectively. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $56,034 and $49,967, respectively. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $49,233 and $43,166, respectively. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest was restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest was restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018. The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest was restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount for the years ended December 31, 2019 and 2018 was $3,616 and $329, respectively. During September 2019, the notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895 and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the year ended December 31, 2019 was $1,474 and debt discount at December 31, 2019 is $4,421. Amortization for this debt discount for the six months ended June 30, 2020 was $2,948 and debt discount at June 30, 2020 is $1,473. The Note is in default and negotiation of settlement. At June 30, 2020 and December 31, 2019, the principal balance is $333,543, and the accrued interest is $65,597 and $25,127, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At June 30, 2020 and December 31, 2019, the principal balance outstanding is $15,000, and the accrued interest is $1,371. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the accrued interest is $45,533 and $39,466, respectively. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the accrued interest is $3,844 and $3,212, respectively. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 and $42,698 during 2018 and 2019, respectively. The Company repaid a total of $18,464 during the six months ended June 30, 2020. At June 30, 2020 and December 31, 2019, the principal balance is $74,264 and $92,728, respectively. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of March 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the years ended 2019 and 2018 was $7,500 and $4,000, respectively. Repayments of $1,500, $7,000 and $5,000 have been made during 2017, 2018 and 2019, respectively. Additionally, repayment of $3,000 was made during the six months ended June 30, 2020. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2020 and December 31, 2019, the principal balance of the note is $30,000, net of debt discount of $1,500 and $4,500, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount for a total of $18,678 have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2020 and 2019 was $0 and $8,254, respectively, for the restated Note in November 2018. The total debt discounts of $12,381 were fully amortized as of June 30, 2019. As of December 31, 2019, the amount due was $60,000. During January 2020, the Note of $60,000 and the Note of $76,076 (See Note 6(3)) plus accrued interest of $12,149 were combined and restated at a rate of 2.0% monthly due July 2020. At June 30, 2020, the restated principal balance and accrued interest was $148,225 and $16,700, respectively. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021(See Note 12). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in May 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 7). An additional 46,000,000 shares with a fair value of $32,200 were issued due to the default on repayment of the promissory note. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2020 and December 31, 2019, the principal balance of the loan is $77,000 and $120,000, net of discount of $7,000 and $0, respectively. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. In September 2018, 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600. At June 30, 2020 and December 31, 2019, the principal balance of the note is $18,000 and the accrued interest is $2,000. (3) At June 30, 2020 and December 31, 2019, the balance of $912,216 and $872,256 net of discount of $3,084 and $17,370, respectively, consisted of the following convertible loans: ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and was due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019, the convertible note payable was recorded at $76,076 with accrued interest of $12,149. During January 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated with principal balance of $148,225. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021 (See Note 12). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. In April 2018, 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500. At June 30, 2020 and December 31, 2019, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 was $589,829. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share in 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in August and October 2020 and are currently in default and in negotiation of settlement. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800. The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November and December 2019, we issued two convertible promissory notes to two unrelated third parties for $159,500 with original issuance discount of $14,500. The notes were due six months from the execution and funding of each note. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price ranging from $0.0002 to $0.000275. The Notes are in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stock as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. Amortization for the year ended December 31, 2019 was $55,222. Additionally, $17,370 was amortized during the six months ended June 30, 2020. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 is $736,180. Two of the above mentioned convertible notes payable for a total of $19,500 was settled in full in March and April 2021(See Note 12). During the six months ended June 30, 2020, we issued convertible notes payable of $101,750 with original issuance discount of $9,250. Amortization for this discount for the six months ended June 30, 2020 was $6,166. $68,750 of these notes were due in a year, and $33,000 of the Notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0002 to 0.0005 per share. At June 30, 2020, the principal balance of the notes, net of discount of $3,084 is $852,216. At the date of the report, all of the above mentioned convertible notes payable are in default and in negotiation of settlement. (4) At June 30, 2020 and December 31, 2019, the balance of $3,613,041 and $5,814,047 net of discount of $0 and $22,344, respectively, consisted of the following convertible loans: ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At June 30, 2020 and December 31, 2019, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $55,815 and $56,373, respectively. ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. During December 2019, the principal balance of $16,752 with accrued interest of $3,232 assigned and sold to a third party was settled as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. At June 30, 2020 and December 31, 2019, the remaining principal of $12,629 plus accrued interest of $11,045 and $9,782, at fair value, was recorded at $55,240 and $62,253. The remaining principal balance of the Note is in default. All of the convertible notes discussed below are with a single unrelated third party. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. The conversion discount was further decreased to fifty percent due to the default on the Note. During September 2018, the Noteholder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At June 30, 2020 and December 31, 2019, the convertible note payable with principal balance of $38,301, at fair value, was recorded at $151,052 and $246,819. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At June 30, 2020 and December 31, 2019, the convertible note payable with principal balance of $220,000, at fair value, was recorded at $864,535 and $1,412,175. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued intere

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Deficit	7 . STOCKHOLDERS’ DEFICIT Authorized Shares On March 7, 2018, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 2,000,000,000 to 8,000,000,000. Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 shares of stock designated “preferred shares”, issuable from time to time in one or more series and authorize the Board of Directors to fix the number of shares constituting any such series, and to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, right and terms of redemption (including sinking fund provisions), the redemption price or prices and the liquidation preference of any wholly unissued series of such preferred shares, and the number of shares constituting any such series. Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 shares of Series A Preferred Stock (“Series A Preferred”). Terms of the Series A Preferred include the following: 1. The Series A Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred will have the same record and payment date and terms as the dividend payable on the common stock. 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series A Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $0.133 in cash per share before any distribution is made on any shares of the Company’s common stock. If upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the application of all amounts available for payments with respect to Series A Preferred would not result in payment in full of Series A Preferred, the holders shall share equally and ratably in any distribution of assets of the Company in proportion to the full liquidation preference to which each is entitled. 4. The Series A Preferred does not have any redemption rights. Common Stock Issued for Conversion of Convertible Debt During January and February 2020, the Note holder made conversions of a total of 500,000,000 shares of stock satisfying the principal balance of $175,000 of a Note originated in February 2019 in the amount of up to $1,000,000(See Note 6). Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 Common Stock Issued for Settlement of Debt During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 6). Common Stock Issued for Debt Modification and Penalty During January and March 2020, we issued a total of 121,000,000 shares to two Note holders due to the default on repayment of the promissory notes. The shares were valued at fair value of $77,200. During June 2020, we issued 5,000,000 shares due to the default on repayment of a related party Note of $14,400 amended in December 2018. The shares were valued at fair value of $3,000. Common Stock Issued for Services During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The shares were valued at $0.0012 per share. The compensation charge of $120,000 has been fully amortized as of June 2019. The Company recorded an equity compensation charge of $0 and $26,500 during the three months ended June 30, 2020 and 2019. The Company recorded an equity compensation charge of $0 and $56,500, respectively, during the six months ended June 30, 2020 and 2019. During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. The equity compensation charge of $21,500 has been recorded during June through December 2019. $1,000 and $8,500 has been recorded during the three and six months ended June 30, 2020.

Stock Warrants

Stock Warrants	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock Warrants	8. STOCK WARRANTS Common Stock Warrants On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $0 and $539 using the Black-Scholes method on June 30, 2020 and December 31, 2019. The warrants expired on March 30, 2020. On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $517 and $872 using the Black-Scholes method at June 30, 2020 and December 31, 2019. The warrants expired on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants expired on April 4, 2019. During April 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 9, 2019. The Company granted the following warrants at an exercise price of $0.001 per share in connection with issuances of three convertible notes payable of $70,000 in February 2019 and amendment of one convertible notes payable of $22,000 in December 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the six months ended June 30, 2020 and the year ended December 31, 2019: Number Of shares Weighted average exercise price Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued - - Expired (6,000,000 ) 0.005 Balance June 30, 2020 46,500,000 $ 0.0026 The following table summarizes information about fixed-price warrants outstanding as of June 30, 2020 and December 31, 2019 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price June 30, 2020 $ 0.001-0.03 46,500,000 0.17 years $ 0.0026 December 31, 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028 At June 30, 2020, the aggregate intrinsic value of all warrants outstanding and expected to vest was $0. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0007, the closing stock price of our restricted common stock on June 30, 2020. There were no in-the-money warrants at June 30, 2020.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses	9. ACCRUED EXPENSES Accrued expenses consisted of the following: June 30, 2020 December 31,2019 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 35,000 35,000 Accrued payroll taxes 191,817 167,906 Accrued interest 279,975 231,186 Accrued others 14,013 16,905 Total $ 682,355 $ 612,547

Prepaid Expenses

Prepaid Expenses	6 Months Ended
	Jun. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	10. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: June 30, 2020 December 31, 2019 Supplier advances for future purchases $ 235,474 $ 224,859 Reserve for supplier advances (224,859 ) (224,859 ) Net supplier advances 10,615 - Prepaid professional fees 4,650 8,650 Deferred stock compensation - 8,500 Total $ 15,265 $ 17,150 We performed an evaluation of our inventory and related accounts at June 30, 2020 and December 31, 2019, and increased the reserve on supplier advances for future venom purchases by $0 and $23,948, respectively. At June 30, 2020 and December 31, 2019, the total valuation allowance for prepaid venom is $224,859.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into our current three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. The lease was month-to-month and terminated in May 2020, thus classified as short-term and not reported on the balance sheet under ASC 842. ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. June 30, 2020 Lease cost Operating lease cost $ 44,510 Short-term lease cost 18,698 Total lease cost $ 63,208 Balance sheet information Operating ROU Assets $ 168,234 Operating lease obligations, current portion 77,945 Operating lease obligations, non-current portion 103,432 Total operating lease obligations $ 181,377 Weighted average remaining lease term (in years) – operating leases 2.17 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the six months ended June 30, 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 40,437 Future minimum payments under these lease agreements are as follows: December 31, Total 2020(Remaining six months) $ 44,687 2021 91,379 2022 62,274 Total future lease payments $ 198,340 Less imputed interest 16,963 Total $ 181,377 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of June 30, 2020 and December 31, 2019. We have accrued the $142,500 in accrued expense and equity compensation. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of June 30, 2020 and December 31, 2019, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. On June 24, 2021, the parties entered into a confidential settlement agreement of the lawsuit. Nutra Pharma has fully performed under the settlement and considers the case fully resolved. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023. The lawsuit was settled on February 15, 2019 for $104,000 and was further amended. The repayments were made in full as of November 2020 (See Note 6). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At June 30, 2020, we owed principal balance of $91,156 and accrued interest of $32,676 (See Note 6) if the defenses and our new claims are deemed to be of no merit. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. At this time the Court has not ruled on the pending Motion. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS Convertible Notes Payable During August 2020, the convertible promissory notes of $38,500 was amended with additional original issuance discount of $7,550 due February 2021. During October 2020, the convertible promissory note of $16,500 was amended with additional original issuance discount (OID) of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The gross proceeds of the notes were allocated to debt and warrants issued on a relative fair value basis. The debt discounts associated with the warrants and OID for $29,481 and $9,200, respectively, are amortized over the life of the notes. Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration August, 2020 92,100,000 $ 20,848 August, 2021 October, 2020 39,930,000 $ 8,633 October, 2022 Pursuant to the Note agreement in the amount up to $1,000,000 signed in February 2019, the principal balance of the note at June 30, 2020 was $116,748. Proceeds in the amount of $87,345 have been funded subsequent to June 30, 2020. During February through June 2021, the Note holder received a total of 240,350,000 shares of our restricted common stock in satisfaction the $120,175 of the Note with a fair value of $2,344,399. The remaining balance of $83,917 is due April 2023. Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 During August 2020, we issued a convertible promissory note to an unrelated third party for a $22,000 with original issuance discount of $2,000. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The note is due August 2021. During July 2020, we issued a convertible promissory note to an unrelated third party for $20,900 with original issuance discount of $1,900. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00052. The note was due January 2021. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The note was due February 2021. The Note is in default and negotiation of settlement. During October and November 2020, we issued convertible promissory notes to 3 unrelated third parties for $208,800 with original issuance discount of $19,800. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.00022 to $0.0005 per share. The notes were due in April and May 2021. The Notes are in default and negotiation of settlement. During November 2020, we issued a convertible promissory note to an unrelated third party for $139,150 with original issuance discount of $12,650. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00055. The note is due November 2021. During November and December 2020, we issued two convertible promissory notes to unrelated third parties for a total of $57,500 with original issuance discount of $7,500. The notes are due one year from the execution and funding of the notes. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0008. In connection with the issuance of convertible notes, the Company granted the 71,875,000 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance. The warrants are valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The gross proceeds of the notes were allocated to debt and warrants issued on a relative fair value basis. The debt discounts associated with the warrants and OID for $30,417 and $7,500, respectively, are amortized over the life of the notes. During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note restated in January 2019 to a third party. The third party subsequently received a total of 100,000,000 shares of our restricted common stock in satisfaction the $20,000 of the Note with a fair value of $140,000. At December 31, 2020, the balance of $55,900 remains outstanding. The note was due January 2021. The Note is in default and negotiation of settlement. During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $717,667 with original issuance discount of $93,609. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0003 to $0.002 per share. The notes are due one year from the execution and funding of the notes.During the second quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $864,225 with original issuance discount of $112,725. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0008 to $0.002 per share. The notes are due one year from the execution and funding of the notes. During July 2021, we issued convertible promissory notes to the unrelated third parties for a total of $16,100 with original issuance discount of $2,100. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.002 per share. The notes are due one year from the execution and funding of the notes. Restatement of Promissory Notes During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. During February 2021, we issued 29,072,500 shares of common stock to satisfy the accrued interest of $23,258 with fair value of $343,056. The settlement of accrued interest resulted in a loss on settlement of debt in other income for $319,798. The principal balance of $166,926 was further restated. The restated balance is $183,619 with an original issuance discount of $16,693 and is due August 2021. Settlement of Convertible Promissory Notes During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on June 30, 2020 was $553,301. During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. During October 2020, the Note holder sold the remaining debt of $467,319 and accrued interest of $166,168 for $250,000 to a non-related party. Number of Fair Value of Date shares converted Debt Converted 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691 During March 2021, in connection with this settlement of the $6,000 of the Note of $11,000 originated in November 2018, we issued 11,000,000 shares of common stocks in satisfaction of $6,000 of the Note with a fair value of $104,500 and made a repayment of $5,000 in cash. The settlement resulted in a loss on settlement of debt in other expense for $98,500. During April 2021, in connection with this settlement of the remaining balance of $8,500 of the Note of $12,000 originated in December 2018, we issued 2,000,000 shares of common stocks in satisfaction of $4,000 of the Note with a fair value of $15,200 and made a repayment of $4,500 in cash. The settlement resulted in a loss on settlement of debt in other expense for $11,200. Common Stock Issued for Default Payments During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500. Common Stock Issued for Consulting Service During June 2021, the Company signed an agreement with a consultant for services for six months for which the Company is to issue 30,000,000 shares of the Company’s restricted common stock. 5,000,000 of the shares were issued upon execution of the agreement and 5,000,000 shares will be issued every 30 days through November 2021. The compensation charge will be amortized over the term of the agreement. Convertible notes receivable On March 10, 2021, we purchased a convertible note from an unrelated third party for a total of $26,950 with original issuance discount of $2,450. The note is convertible into common shares for $0.01 per common share and mature on March 10, 2022. On May 20, 2021, we purchased a convertible note from an unrelated third party for a total of $145,200 with original issuance discount of $13,200. The note is convertible into common shares for $0.01 per common share and mature on May 20, 2022.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Organization	Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ®
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Liquidity and Going Concern	Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $67,187,729 at June 30, 2020. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $10,055,035 and a stockholders’ deficit of $10,431,780 at June 30, 2020. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Impact of COVID-19 on our Operations	Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $64,895. We used the proceeds primarily for payroll costs. We expect forgiveness of this loan under the current terms of requirement by the SBA. During April and June 2020, we obtained a loan in the amount of $150,000 from SBA under its Economic Injury Disaster Loan assistance program. We used the proceeds primarily for rent, payroll, utilities, accounting and legal expenses (See Note 6). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine.
Use of Estimates	Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers	Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No allowance for doubtful account is deemed to be required at June 30, 2020 and December 31, 2019.
Inventories	Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at June 30, 2020 and December 31, 2019, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $0 and $23,948, respectively. At both June 30, 2020 and December 31, 2019, the total valuation allowance for prepaid venom was $224,859.
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended June 30, 2020, there was no customer accounted for more than 10% of the total revenues. For the three months ended June 30, 2019, there was one customer that accounted for 27% of the total revenues. For the six months ended June 30, 2020, there was one customer that accounted for 43% of the total revenues. For the six months ended June 30, 2019, there were two customers that accounted for 25% and 49% of the total revenues, respectively. As of June 30, 2020 and December 31, 2019, 100% of the accounts receivable balance are reserves due from two payment processors.
Operating Lease Right-of-Use Asset and Liability	Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate.
Derivative Financial Instruments	Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt	Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
The Fair Value Measurement Option	The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging
Derivative Accounting for Convertible Debt and Options and Warrants	Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
Long-Lived Assets	Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.
Income Taxes	Income Taxes The Company recorded no income tax expense for the six months ended June 30, 2020 and 2019 because the estimated annual effective tax rate was zero. As of June 30, 2020, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation
Net Income (Loss) Per Share	Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Basic and diluted numerator: Net income (loss) - basic $ (1,506,489 ) $ (1,668,207 ) $ 676,555 $ (2,068,650 ) Effect of dilutive securities: Change in fair value of convertible notes - - (1,818,618 ) - Interest on convertible debt - - 16,167 - Net loss - diluted $ (1,506,489 ) $ (1,668,207 ) $ (1,125,896 ) $ (2,068,650 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 6,623,845,012 4,612,987,869 6,448,086,770 4,336,212,961 Effect of dilutive securities: Convertible debt - - 6,523,893,291 - Weighted-average common shares outstanding - diluted (1) 6,623,845,012 4,612,987,869 12,971,980,061 4,336,212,961 Net income (loss) per share - basic and diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. As of June 30, 2020 and 2019, the following items were not included in dilutive loss as the effect is anti-dilutive: June 30, 2020 June 30, 2019 Options and warrants 46,500,000 118,500,000 Convertible notes payable at fair value - 7,050,986,979 Convertible notes payable - 1,230,580,833 Total 46,500,000 8,400,067,812
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Basic and diluted numerator: Net income (loss) - basic $ (1,506,489 ) $ (1,668,207 ) $ 676,555 $ (2,068,650 ) Effect of dilutive securities: Change in fair value of convertible notes - - (1,818,618 ) - Interest on convertible debt - - 16,167 - Net loss - diluted $ (1,506,489 ) $ (1,668,207 ) $ (1,125,896 ) $ (2,068,650 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 6,623,845,012 4,612,987,869 6,448,086,770 4,336,212,961 Effect of dilutive securities: Convertible debt - - 6,523,893,291 - Weighted-average common shares outstanding - diluted (1) 6,623,845,012 4,612,987,869 12,971,980,061 4,336,212,961 Net income (loss) per share - basic and diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares.
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share	As of June 30, 2020 and 2019, the following items were not included in dilutive loss as the effect is anti-dilutive: June 30, 2020 June 30, 2019 Options and warrants 46,500,000 118,500,000 Convertible notes payable at fair value - 7,050,986,979 Convertible notes payable - 1,230,580,833 Total 46,500,000 8,400,067,812

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Summary of Financial Instruments Measured at Fair Value	The following table summarizes our financial instruments measured at fair value at June 30, 2020 and December 31, 2019: Fair Value Measurements at June 30, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 517 $ - $ - $ 517 Derivative liabilities $ 1,336,598 $ - $ - $ 1,336,598 Convertible notes at fair value $ 3,613,041 $ - $ - $ 3,613,041 Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ - $ 834,457 Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the six months ended June 30, 2020 and the year ended December 31, 2019: Description June 30, 2020 December 31, 2019 Beginning balance $ 1,411 $ 1,468 Total gain included in earnings (1) (894 ) (57 ) Ending balance $ 517 $ 1,411 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
Summary of Assumptions and the Significant Terms	The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at June 30, 2020 and December 31, 2019: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back June 30, 2020 $ 1,088,578 8%-10% 20%-24% N/A $0.00025-$0.00044 50%-60% 3 to 25 Days December 31, 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days
Convertible Notes Payable [Member]
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2020 and the year ended December 31, 2019: Description June 30, 2020 December 31, 2019 Beginning balance $ 5,814,047 $ 1,156,341 Purchases and issuances 19,374 688,274 Day one loss on value of hybrid instrument (1) 24,598 926,109 Loss (gain) from change in fair value (1) (1,842,322 ) 3,423,935 Debt discount 22,344 (22,344 ) Settlement through issuance of common stock - (83,268 ) Conversion to common stock (425,000 ) (275,000 ) Ending balance $ 3,613,041 $ 5,814,047 (1) The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are valued at the lower of cost or net realizable value on an average cost basis. At June 30, 2020 and December 31, 2019, inventories were as follows: June 30, 2020 December 31, 2019 Raw Materials $ 65,568 $ 52,183 Finished Goods 6,376 8,177 Total Inventories 71,944 60,360 Less: Long-term inventory (65,568 ) (52,183 ) Current portion $ 6,376 $ 8,177

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following at June 30, 2020 and December 31, 2019: June 30, 2020 December 31, 2019 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (210,694 ) (209,270 ) Property and equipment, net $ 5,339 $ 6,763

Debts (Tables)

Debts (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Debt	Debts consist of the following at June 30, 2020 and December 31, 2019: June 30, 2020 December 31, 2019 Note payable– Related Party (1) $ - $ 14,400 Notes payable – Unrelated third parties (Net of discount of $9,972 and $8,921, respectively) (2) 1,382,898 1,385,163 Convertible notes payable – Unrelated third parties (Net of discount of $3,084 and $17,370, respectively) (3) 912,216 872,256 Convertible notes payable, at fair value (Net of discount of $0 and $22,344, respectively) (4) 3,613,041 5,814,047 Other advances from an unrelated third party (5) 225,000 175,000 SBA notes payable(6) 214,795 - Ending balances 6,347,950 8,260,866 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (306,462 ) (907,912 ) Less: Long-term portion- SBA notes payable (214,795 ) - Current portion $ 5,826,693 $ 7,352,954 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid the principal balance in full as of December 31, 2016. At June 30, 2020 and December 31, 2019, we owed this director accrued interest of $169,190 and $159,555, respectively. The interest expense for the six-months ended June 30, 2020 and 2019 was $9,635 and $8,564, respectively, and $4,914 and $4,368 for the three-months ended June 30, 2020 and 2019, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. The Note of $14,400 was paid in full in cash during June 2020. In addition, we issued 5,000,000 shares due to the default on repayment of the note. The shares were valued at fair value of $3,000(See Note 7). At June 30, 2020 and December 31, 2019, the principal balance of the loan is $0 and $14,400. (2) At June 30, 2020 and December 31, 2019, the balance of $1,382,898 and $1,385,163 net of discount of $9,972 and $8,921, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 12) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2020 and December 31, 2019, the accrued interest is $4,258 and $3,755, respectively. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $56,034 and $49,967, respectively. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $49,233 and $43,166, respectively. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest was restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest was restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018. The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest was restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount for the years ended December 31, 2019 and 2018 was $3,616 and $329, respectively. During September 2019, the notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895 and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the year ended December 31, 2019 was $1,474 and debt discount at December 31, 2019 is $4,421. Amortization for this debt discount for the six months ended June 30, 2020 was $2,948 and debt discount at June 30, 2020 is $1,473. The Note is in default and negotiation of settlement. At June 30, 2020 and December 31, 2019, the principal balance is $333,543, and the accrued interest is $65,597 and $25,127, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At June 30, 2020 and December 31, 2019, the principal balance outstanding is $15,000, and the accrued interest is $1,371. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the accrued interest is $45,533 and $39,466, respectively. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the accrued interest is $3,844 and $3,212, respectively. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 and $42,698 during 2018 and 2019, respectively. The Company repaid a total of $18,464 during the six months ended June 30, 2020. At June 30, 2020 and December 31, 2019, the principal balance is $74,264 and $92,728, respectively. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of March 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2020 and December 31, 2019, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the years ended 2019 and 2018 was $7,500 and $4,000, respectively. Repayments of $1,500, $7,000 and $5,000 have been made during 2017, 2018 and 2019, respectively. Additionally, repayment of $3,000 was made during the six months ended June 30, 2020. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2020 and December 31, 2019, the principal balance of the note is $30,000, net of debt discount of $1,500 and $4,500, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount for a total of $18,678 have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2020 and 2019 was $0 and $8,254, respectively, for the restated Note in November 2018. The total debt discounts of $12,381 were fully amortized as of June 30, 2019. As of December 31, 2019, the amount due was $60,000. During January 2020, the Note of $60,000 and the Note of $76,076 (See Note 6(3)) plus accrued interest of $12,149 were combined and restated at a rate of 2.0% monthly due July 2020. At June 30, 2020, the restated principal balance and accrued interest was $148,225 and $16,700, respectively. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021(See Note 12). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in May 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 7). An additional 46,000,000 shares with a fair value of $32,200 were issued due to the default on repayment of the promissory note. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2020 and December 31, 2019, the principal balance of the loan is $77,000 and $120,000, net of discount of $7,000 and $0, respectively. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. In September 2018, 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600. At June 30, 2020 and December 31, 2019, the principal balance of the note is $18,000 and the accrued interest is $2,000. (3) At June 30, 2020 and December 31, 2019, the balance of $912,216 and $872,256 net of discount of $3,084 and $17,370, respectively, consisted of the following convertible loans: ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and was due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019, the convertible note payable was recorded at $76,076 with accrued interest of $12,149. During January 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated with principal balance of $148,225. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021 (See Note 12). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. In April 2018, 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500. At June 30, 2020 and December 31, 2019, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 was $589,829. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share in 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in August and October 2020 and are currently in default and in negotiation of settlement. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800. The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November and December 2019, we issued two convertible promissory notes to two unrelated third parties for $159,500 with original issuance discount of $14,500. The notes were due six months from the execution and funding of each note. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price ranging from $0.0002 to $0.000275. The Notes are in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stock as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. Amortization for the year ended December 31, 2019 was $55,222. Additionally, $17,370 was amortized during the six months ended June 30, 2020. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 is $736,180. Two of the above mentioned convertible notes payable for a total of $19,500 was settled in full in March and April 2021(See Note 12). During the six months ended June 30, 2020, we issued convertible notes payable of $101,750 with original issuance discount of $9,250. Amortization for this discount for the six months ended June 30, 2020 was $6,166. $68,750 of these notes were due in a year, and $33,000 of the Notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0002 to 0.0005 per share. At June 30, 2020, the principal balance of the notes, net of discount of $3,084 is $852,216. At the date of the report, all of the above mentioned convertible notes payable are in default and in negotiation of settlement. (4) At June 30, 2020 and December 31, 2019, the balance of $3,613,041 and $5,814,047 net of discount of $0 and $22,344, respectively, consisted of the following convertible loans: ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At June 30, 2020 and December 31, 2019, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $55,815 and $56,373, respectively. ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. During December 2019, the principal balance of $16,752 with accrued interest of $3,232 assigned and sold to a third party was settled as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. At June 30, 2020 and December 31, 2019, the remaining principal of $12,629 plus accrued interest of $11,045 and $9,782, at fair value, was recorded at $55,240 and $62,253. The remaining principal balance of the Note is in default. All of the convertible notes discussed below are with a single unrelated third party. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. The conversion discount was further decreased to fifty percent due to the default on the Note. During September 2018, the Noteholder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At June 30, 2020 and December 31, 2019, the convertible note payable with principal balance of $38,301, at fair value, was recorded at $151,052 and $246,819. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At June 30, 2020 and December 31, 2019, the convertible note payable with principal balance of $220,000, at fair value, was recorded at $864,535 and $1,412,175. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at def
Schedule of Future Minimum Principal Payment	At June 30, 2020, the future minimum principal payments for the above mentioned PPP and EIDL loans are as follows: Years Amount 2021 $ 10,726 2022 56,290 2023 3,283 2024 3,408 2025 3,538 Thereafter 137,650 $ 214,895

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000

Stock Warrants (Tables)

Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Warrants Issued	The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020
Summary of Warrants Outstanding	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the six months ended June 30, 2020 and the year ended December 31, 2019: Number Of shares Weighted average exercise price Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued - - Expired (6,000,000 ) 0.005 Balance June 30, 2020 46,500,000 $ 0.0026
Summary of Fixed Price Warrants Outstanding	The following table summarizes information about fixed-price warrants outstanding as of June 30, 2020 and December 31, 2019 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price June 30, 2020 $ 0.001-0.03 46,500,000 0.17 years $ 0.0026 December 31, 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: June 30, 2020 December 31,2019 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 35,000 35,000 Accrued payroll taxes 191,817 167,906 Accrued interest 279,975 231,186 Accrued others 14,013 16,905 Total $ 682,355 $ 612,547

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses	Prepaid expenses and other current assets consist of the following: June 30, 2020 December 31, 2019 Supplier advances for future purchases $ 235,474 $ 224,859 Reserve for supplier advances (224,859 ) (224,859 ) Net supplier advances 10,615 - Prepaid professional fees 4,650 8,650 Deferred stock compensation - 8,500 Total $ 15,265 $ 17,150

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost and Balance Sheet Information	June 30, 2020 Lease cost Operating lease cost $ 44,510 Short-term lease cost 18,698 Total lease cost $ 63,208 Balance sheet information Operating ROU Assets $ 168,234 Operating lease obligations, current portion 77,945 Operating lease obligations, non-current portion 103,432 Total operating lease obligations $ 181,377 Weighted average remaining lease term (in years) – operating leases 2.17 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the six months ended June 30, 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 40,437
Schedule of Future Minimum Payments Under Lease Agreements	Future minimum payments under these lease agreements are as follows: December 31, Total 2020(Remaining six months) $ 44,687 2021 91,379 2022 62,274 Total future lease payments $ 198,340 Less imputed interest 16,963 Total $ 181,377

Subsequent Events (Tables)

Subsequent Events (Tables)	6 Months Ended
	Jun. 30, 2020
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000
Convertible Notes Payable [Member]
Summary of Warrants Issuance	Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration August, 2020 92,100,000 $ 20,848 August, 2021 October, 2020 39,930,000 $ 8,633 October, 2022
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250
Settlement of Convertible Promissory Notes [Member]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2018
Accumulated deficit		$ (67,187,729)		$ (67,187,729)		$ (67,864,284)
Working capital		(10,055,035)		(10,055,035)		(10,931,827)
Stockholders' deficit		(10,431,780)	$ (7,652,158)	(10,431,780)	$ (7,652,158)	(11,701,035)	$ (8,928,291)	$ (6,296,489)	$ (5,936,593)
Change in reserve for supplier advances for purchases				0		23,948
Inventory adjustments		224,859		224,859		$ 224,859
Provision for income taxes
Minimum [Member]
Property and equipment estimated useful lives				3 years
Maximum [Member]
Property and equipment estimated useful lives				7 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer No [Member]
Concentration risk, percentage		10.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration risk, percentage			27.00%	43.00%	25.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration risk, percentage					49.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration risk, percentage				100.00%		100.00%
PPP [Member]
Proceeds form loan	$ 64,895	$ 150,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Net income (loss) - basic		$ (1,506,489)	$ (1,668,207)	$ 676,555	$ (2,068,650)
Change in fair value of convertible notes				(1,818,618)
Interest on convertible debt				16,167
Net loss - diluted		$ (1,506,489)	$ (1,668,207)	$ (1,125,896)	$ (2,068,650)
Weighted-average common shares outstanding - basic		6,623,845,012	4,612,987,869	6,448,086,770	4,336,212,961
Convertible debt				6,523,893,291
Weighted-average common shares outstanding - diluted	[1]	6,623,845,012	4,612,987,869	12,971,980,061	4,336,212,961
Net income (loss) per share - basic and diluted		$ 0	$ 0	$ 0	$ 0
[1]	Includes potential common shares that are in excess of authorized shares.

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive securities excluded from computation of earnings per share	46,500,000	8,400,067,812
Options and Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	46,500,000	118,500,000
Convertible Notes Payable at Fair Value [Member]
Antidilutive securities excluded from computation of earnings per share		7,050,986,979
Convertible Notes Payable [Member]
Antidilutive securities excluded from computation of earnings per share		1,230,580,833

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	Jun. 30, 2020
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants outstanding, measurement input, percentage	0.17
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants outstanding, measurement input, percentage	1.59
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants outstanding, measurement input, percentage	320
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants outstanding, measurement input, percentage	348
Measurement Input, Expected Dividend Rate [Member]
Warrants outstanding, measurement input, percentage	0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Warrant liability	$ 517	$ 1,411
Derivative liabilities	1,336,598	834,457
Convertible notes at fair value	3,613,041	5,814,047
Fair Value, Inputs, Level 1 [Member]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 2 [Member]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Warrant liability	517	1,411
Derivative liabilities	1,336,598	834,457
Convertible notes at fair value	$ 3,613,041	$ 5,814,047

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)		6 Months Ended	12 Months Ended
		Jun. 30, 2020	Dec. 31, 2019
Convertible Notes Payable [Member]
Beginning balance		$ 5,814,047	$ 1,156,341
Purchases and issuances		19,374	688,274
Day one loss on value of hybrid instrument	[1]	24,598	926,109
Loss (gain) from change in fair value	[1]	(1,842,322)	3,423,935
Debt discount		22,344	(22,344)
Settlement through issuance of common stock			(83,268)
Conversion to common stock		(425,000)	(275,000)
Ending balance		3,613,041	5,814,047
Warrants [Member]
Beginning balance		1,411	1,468
Total gain included in earnings	[2]	(894)	(57)
Ending balance		$ 517	$ 1,411
[1]	The losses (gains) related to the valuation of the convertible notes are included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.
[2]	The gain related to the revaluation of our warrant liability is included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Assumptions and the Significant Terms (Details) - Convertible Notes Payable [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)d$ / shares	Dec. 31, 2019USD ($)d$ / shares
Face Amount | $	$ 1,088,578	$ 1,244,204
Minimum [Member]
Conversion Price | $ / shares	$ 0.00025	$ 0.00010
Percentage of stock price for look-back period	50.00%	50.00%
Look-back period | d	3	3
Maximum [Member]
Conversion Price | $ / shares	$ 0.00044	$ 0.000293
Percentage of stock price for look-back period	60.00%	60.00%
Look-back period | d	25	25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	8	8
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	10	10
Measurement Input, Default Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	20	20
Measurement Input, Default Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	24	24
Measurement Input, Discount Rate [Member]
Long-term debt, measurement input

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw Materials	$ 65,568	$ 52,183
Finished Goods	6,376	8,177
Total Inventories	71,944	60,360
Less: Long-term inventory	(65,568)	(52,183)
Current portion	$ 6,376	$ 8,177

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 712	$ 1,105	$ 1,424	$ 2,210

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property and equipment, gross	$ 216,033	$ 216,033
Less: Accumulated depreciation	(210,694)	(209,270)
Property and equipment, net	5,339	6,763
Computer Equipment [Member]
Property and equipment, gross	25,120	25,120
Furniture and Fixtures [Member]
Property and equipment, gross	34,757	34,757
Lab Equipment [Member]
Property and equipment, gross	53,711	53,711
Telephone Equipment [Member]
Property and equipment, gross	12,421	12,421
Office Equipment - Other [Member]
Property and equipment, gross	16,856	16,856
Leasehold Improvements [Member]
Property and equipment, gross	$ 73,168	$ 73,168

Due to_from Officer (Details Na

Due to/from Officer (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Due to officer	$ 193,216		$ 193,216		$ 122,812
Repayment of officers loans			15,450	$ 61,715
Loans from officer			152,700	4,100
Accrued interest expense for amount due to officer			3,654	3,536
Company other receivable reserves	493,970		493,970		564,470
Bad debt expense				31,789
Rik Deitsch [Member]
Due to officer	$ 193,216		$ 193,216		$ 122,812
Bears interest percentage	4.00%		4.00%		4.00%
Repayment of officers loans			$ 15,450		$ 134,015
Loans from officer			152,700		5,000
Accrued interest expense for amount due to officer			3,654		$ 6,330
Bad debt expense	$ 31,000	$ 0	$ 70,500	$ 0

Debts - Schedule of Debt (Detai

Debts - Schedule of Debt (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Note payable- Related Party		$ 14,400
Notes payable - Unrelated third parties (Net of discount of $9,972 and $8,921, respectively)	1,382,898	1,385,163
Convertible notes payable - Unrelated third parties (Net of discount of $3,084 and $17,370, respectively)	912,216	872,256
Convertible notes payable, at fair value (Net of discount of $0 and $22,344, respectively)	3,613,041	5,814,047
Other advances from an unrelated third party	225,000	175,000
SBA notes payable	214,795
Ending balances	6,347,950	8,260,866
Less: Long-term portion-Convertible Notes payable-Unrelated third parties	(306,462)	(907,912)
Less: Long-term portion- SBA notes payable	(214,795)
Current portion	$ 5,826,693	$ 7,352,954

Debts - Schedule of Debt (Det_2

Debts - Schedule of Debt (Details) (Parenthetical)	Jun. 30, 2021USD ($)$ / shares	Jul. 31, 2020USD ($)	Feb. 18, 2020USD ($)shares	Jan. 21, 2020USD ($)shares	Feb. 15, 2019USD ($)	Aug. 14, 2018USD ($)shares	Jul. 31, 2018USD ($)shares	Feb. 28, 2018USD ($)	Jul. 31, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Mar. 28, 2016USD ($)	Jun. 30, 2012USD ($)	Jun. 30, 2021USD ($)$ / shares	Apr. 30, 2021USD ($)	Feb. 28, 2021USD ($)	Oct. 31, 2020USD ($)$ / shares	Aug. 31, 2020USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	May 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Jun. 30, 2019USD ($)shares	May 31, 2019USD ($)shares	Feb. 28, 2019USD ($)$ / sharesshares	Jan. 31, 2019USD ($)	Sep. 30, 2018USD ($)shares	Aug. 31, 2018USD ($)dshares	Jul. 31, 2018USD ($)dshares	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)dshares	May 31, 2018USD ($)d	Apr. 30, 2018USD ($)dshares	Feb. 28, 2018USD ($)d	Sep. 30, 2017USD ($)	May 31, 2017USD ($)d	Apr. 30, 2017USD ($)shares	Dec. 31, 2016USD ($)dshares	Feb. 29, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Jul. 31, 2017USD ($)shares	Jun. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Jun. 30, 2019USD ($)	Mar. 31, 2012USD ($)shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)d$ / sharesshares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)d$ / sharesshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)shares	Mar. 31, 2021$ / shares	Dec. 31, 2020USD ($)shares	Nov. 30, 2020USD ($)$ / shares	Sep. 30, 2020USD ($)	Jan. 31, 2020USD ($)	Nov. 30, 2019USD ($)$ / shares	Jul. 31, 2019USD ($)	Jun. 17, 2019USD ($)shares	Oct. 31, 2018USD ($)	Jul. 12, 2018USD ($)	Apr. 28, 2018USD ($)shares	Nov. 30, 2017USD ($)shares	Oct. 31, 2017USD ($)shares	Oct. 20, 2017USD ($)	Oct. 12, 2017USD ($)	Aug. 31, 2017	Jul. 26, 2017USD ($)$ / shares	Feb. 28, 2017$ / shares	Jan. 31, 2017USD ($)	Oct. 31, 2016USD ($)	Sep. 26, 2016USD ($)	Aug. 31, 2016USD ($)shares	Jul. 31, 2016USD ($)$ / shares	Jun. 30, 2016USD ($)	May 31, 2016USD ($)	Apr. 30, 2016USD ($)	Apr. 30, 2014$ / sharesshares	Aug. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Feb. 15, 2012USD ($)	Dec. 31, 2011USD ($)	Aug. 15, 2011USD ($)	Aug. 02, 2011USD ($)	Dec. 31, 2010USD ($)	Feb. 28, 2010	Jan. 31, 2010
Notes payable																			$ 6,347,950		$ 8,260,866																					$ 6,347,950					$ 6,347,950		$ 8,260,866
Accrued interest																																															32,676
Interest expense, debt																																										78,238		$ 59,832			147,111	$ 134,977
Debt conversion, converted instrument, shares issued | shares			250,000,000	250,000,000
Repayments of notes payable																																															14,400
Gain loss on extinguishment of debt																																															(22,000)	57,253
Debt instrument accrued interest																																															$ 12,150
Common stock, shares, issued | shares																			6,627,746,111		5,876,746,111																	1,000,000				6,627,746,111					6,627,746,111		5,876,746,111			1,000,000
Common stock issued value																			$ 6,627,746		$ 5,876,746																					$ 6,627,746					$ 6,627,746		$ 5,876,746
Amortization of debt discount																																															58,829	62,078
Repayments of convertible debt																																																10,000
Stock issued price per shares | $ / shares																			$ 0.18		$ 0.18																					$ 0.18					$ 0.18		$ 0.18
Number of shares issued for conversion of debt			$ 275,000	$ 150,000
Number of warrants issued | shares																																																																															100,000
Warrant exercise price | $ / shares																																																																															$ 0.025
Fair Value of Warrants																					$ 7,370				$ 8,147																									$ 0
Month of expiration																																																																															Apr. 9, 2019
Proceeds from issuance of other long term debt																																															$ 50,000
Other advances from an unrelated third party																			$ 225,000		$ 175,000																					$ 225,000					$ 225,000		$ 175,000
Minimum [Member]
Warrant exercise price | $ / shares																			$ 0.03		$ 0.03																					$ 0.03					$ 0.03		$ 0.03
Maximum [Member]
Warrant exercise price | $ / shares																			$ 0.001		$ 0.001																					$ 0.001					$ 0.001		$ 0.001
Subsequent Event [Member] | Warrants [Member]
Debt discount																																																							$ 7,500
Warrant exercise price | $ / shares																																																							$ 0.002
Warrant outstanding																																																							$ 30,417
Fair Value of Warrants																	$ 8,633	$ 20,848
NonRelatedPartyFiveMember
Notes payable																																																														$ 220,506
Debt instrument, interest rate, stated percentage																																																														0.25%
Non Related Party Ten [Member]
Debt discount																			$ 7,000																							$ 7,000					$ 7,000
Notes payable																			$ 77,000																							$ 77,000					$ 77,000
Settlement Agreement [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Cash settlement																																																								$ 84,000
SBA Loan Agreement [Member]
Debt instrument, interest rate, stated percentage																			3.75%																							3.75%					3.75%
Outstanding notes payable																			$ 150,000																							$ 150,000					$ 150,000
Repayments of convertible debt																																										5,000
Debt conversion principle amount																																										731
Convertible Debtentures [Member]
Debt discount																			3,084		$ 17,370																					3,084					3,084		$ 17,370
Notes payable																					22,000																												22,000
Outstanding notes payable																			912,216		872,256																					912,216					912,216		872,256
Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																						12.00%														12.00%
Accrued interest																																		$ 2,820							$ 63,001
Debt conversion, converted instrument, shares issued | shares																																									179,800,000
Common stock, shares, issued | shares							105,157,409																						105,157,409
Common stock issued value							$ 147,220																						$ 147,220
Convertible notes payable																																						$ 110,000												32,400		$ 110,000
Debt maturity date																																						Sep. 8, 2017
Debt conversion principle amount																																		46,999
Debt instrument conversion feature																																									$ 298,575
Conversion percentage																																						60.00%
Trading days | d																																						25
Convertible Debtentures [Member] | Non Related Party Fourteen [Member]
Debt discount																					0							$ 3,800																					0
Notes payable								$ 65,600																										65,600
Accrued interest																												$ 10,476
Debt instrument, unamortized discount net issuance costs						$ 4,035
Debt conversion, converted instrument, shares issued | shares						1,000,000																						5,000,000
Amortization of debt discount																																																950		2,850
Convertible notes payable								$ 65,600													76,076							$ 76,076						$ 65,600															76,076																				$ 56,567		$ 56,567				$ 50,000
Debt instrument convertible debt percentage								2.50%																				2.50%						2.50%																																					2.50%				2.00%
Stock issued price per shares | $ / shares																																																																					$ 0.05						$ 0.05
Back and End Note [Member]
Debt instrument, interest rate, stated percentage																																	8.00%
Debt principal amount																			71,500		71,500												$ 100,000									71,500					71,500		71,500
Convertible notes payable																			280,974		458,957												$ 65,000									280,974					280,974		458,957
Debt instrument convertible debt percentage																																	24.00%
Conversion percentage																																	60.00%
Trading days | d																																	25
Derivative loss																																	$ 110,700
Back and End Note [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																														8.00%	8.00%
Debt principal amount																			66,000		66,000																					66,000					66,000		66,000
Convertible notes payable																			255,958		417,577									$ 60,000	$ 60,000											255,958					255,958		417,577
Debt instrument convertible debt percentage																														24.00%	24.00%
Conversion percentage																															60.00%
Trading days | d																															25
Derivative loss																														$ 68,067	$ 68,067
Restatement of Promissory Notes [Member] | Subsequent Event [Member]
Debt instrument, interest rate, stated percentage		2.00%
Debt principal amount		$ 166,926
Debt instrument accrued interest																$ 23,258
PPP [Member]
Proceeds from issuance of other long term debt																				$ 64,895																											225,000
Note Payable Unrelated Party [Member]
Debt discount																			9,972		8,921																					9,972					9,972		8,921
Non Related Parties Convertible Notes Payable [Member]
Debt discount																			3,084		17,370																					3,084					3,084		17,370
Convertible Notes Payable [Member]
Debt discount																			$ 0		22,344				5,000																	$ 0					$ 0		22,344
Debt instrument, unamortized discount net issuance costs																					5,000																												5,000
Outstanding notes payable																																																		589,829
Amortization of debt discount																								$ 8,200																										28,421
Convertible notes payable																					$ 70,000				$ 70,000																								$ 70,000
Debt instrument convertible debt percentage																									0.05%
Number of warrants issued | shares																					110,000,000																												110,000,000
Warrant exercise price | $ / shares																					$ 0.001																												$ 0.001
Warrant outstanding																					$ 8,147																												$ 8,147
Convertible Notes Payable [Member] | Warrants [Member]
Number of warrants issued | shares																					44,000,000				110,000,000																								44,000,000
Warrant exercise price | $ / shares																					$ 0.001																												$ 0.001
Fair Value of Warrants																					$ 7,370				$ 8,147
Month of expiration																					Aug. 31, 2020				Aug. 31, 2019																								Aug. 31, 2020
Convertible Notes Payable [Member] | Common Stock [Member]
Debt instrument, unamortized discount net issuance costs																								$ 6,400
Common stock, shares, issued | shares																								6,000,001
Common stock issued value																								$ 1,800
Convertible Notes Payable [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares																			$ 0.00025		$ 0.00010																					$ 0.00025					$ 0.00025		$ 0.00010
Conversion percentage																																															50.00%		50.00%
Trading days | d																																															3		3
Convertible Notes Payable [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares																			$ 0.00044		$ 0.000293																					$ 0.00044					$ 0.00044		$ 0.000293
Conversion percentage																																															60.00%		60.00%
Trading days | d																																															25		25
Convertible Notes Payable [Member] | Subsequent Event [Member]
Convertible notes payable																	553,301
Convertible Notes Payable [Member] | Subsequent Event [Member] | Warrants [Member]
Debt discount																	$ 29,481
Warrant exercise price | $ / shares																	$ 0.001
Convertible Notes Payable [Member] | Subsequent Event [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares	$ 0.0008													$ 0.0008																																$ 0.0008							$ 0.0003
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																				8.00%
Accrued interest								$ 63,144													$ 3,232
Debt conversion, converted instrument, shares issued | shares																					800,000,000										50,670,000
Debt principal amount																			$ 12,629		$ 12,629																					$ 12,629					$ 12,629		$ 12,629
Non-payment penalty charges								$ 12,442																										$ 12,442																														$ 6,400
Convertible notes payable																			55,240		62,253									34,060	$ 34,060					$ 64,000						55,240					55,240		62,253															856
Debt maturity date																																				May 4, 2018
Interest payable																			11,045		9,782																					11,045					11,045		9,782
Debt instrument convertible debt percentage																																				20.00%
Deposit liabilities, accrued interest																														8,607	8,607																																	21,399
Debt conversion principle amount																					16,752
Debt instrument conversion feature																															70,938
Conversion percentage																																				60.00%
Trading days | d																																				20
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member]
Accrued interest																																																	12,149
Non-payment penalty charges																																																									$ 148,225
Convertible Notes Payable [Member] | Non Related Party Fifteen [Member]
Debt instrument, unamortized discount net issuance costs																																																																	$ 10,000
Debt default, amount																																																																	$ 3,300
Common stock, shares, issued | shares																																																																	5,000,000
Convertible notes payable																																																																	$ 60,000
Convertible Notes Payable [Member] | Non Related Party Twenty [Member]
Debt discount																																																		255,655
Debt instrument, unamortized discount net issuance costs																																																		$ 62,950
Common stock, shares, issued | shares																																																		10,250,000
Common stock issued value																																																		$ 6,542
Amortization of debt discount																																																		62,950
Convertible notes payable																																																		618,250
Debt instrument conversion feature																																																		$ 249,113
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Minimum [Member]
Debt instrument convertible debt percentage																																																		0.03%
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Maximum [Member]
Debt instrument convertible debt percentage																																																		0.10%
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt discount																			9,250																							9,250					9,250
Notes payable																			101,750																							101,750					101,750
Debt instrument, unamortized discount net issuance costs																					14,500																												14,500									$ 14,500
Convertible notes payable																					$ 159,500																												$ 159,500									$ 159,500
Stock issued price per shares | $ / shares																					$ 0.0002																												$ 0.0002									$ 0.000275
Amortization																																																	$ 55,222
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Minimum [Member]
Notes payable																			$ 33,000																							$ 33,000					33,000
Amortization of debt discount																																															$ 6,166
Stock issued price per shares | $ / shares																			$ 0.0002																							$ 0.0002					$ 0.0002
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Maximum [Member]
Notes payable																			$ 33,000																							$ 33,000					$ 33,000
Amortization of debt discount																																															$ 68,750
Stock issued price per shares | $ / shares																			$ 0.0005																							$ 0.0005					$ 0.0005
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member]
Debt discount		1,900															$ 1,650	7,550
Debt principal amount		20,900															$ 16,500	$ 38,500
Repayments of convertible debt														$ 19,500	$ 19,500
Convertible Notes Payable [Member] | 16 Unrelated Third Parties [Member]
Debt discount																					$ 17,370																												17,370
Convertible notes payable																					736,180																												736,180
Amortization																																															$ 17,370
Convertible Notes Payable [Member] | Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member]
Repayments of notes payable																																																			$ 60,000	$ 40,000
Debt principal amount																			$ 20,000		20,000																					$ 20,000					20,000		20,000
Convertible notes payable												$ 120,000							55,815		56,373																					55,815					55,815		56,373
Debt instrument convertible debt percentage												55.00%
Extinguishment debt extinguishment assets payments												$ 7,000
Derivative, collateral, obligation to return cash												$ 36,000
Convertible Notes Payable [Member] | Note Agreement [Member]
Debt principal amount																			116,748						$ 1,000,000																	116,748					116,748
Proceeds from loan																																															87,345
Convertible Notes Payable [Member] | Note Agreement [Member] | Subsequent Event [Member]
Debt instrument fair value	$ 2,344,399													2,344,399																																$ 2,344,399
Stock issued during period, restricted stock | shares																																														240,350,000
Stock issued during period, restricted stock value																																														$ 120,175
Proceeds from loan	87,345
Convertible Notes Payable [Member] | Promissory Note [Member]
Debt principal amount																										$ 75,000
Convertible notes payable																										60,000
Interest payable																										15,900
Derivative loss																										75,900
Convertible Notes Payable [Member] | Promissory Note [Member] | Settlement Agreement [Member] | Non Related Party Fifteen [Member]
Common stock, shares, issued | shares																																	1,000,000
Common stock issued value																																	$ 1,500
Convertible notes payable																			60,000		60,000																					60,000					60,000		60,000
Convertible Notes Payable [Member] | Convertible Debtentures [Member]
Debt instrument, interest rate, stated percentage																																						8.00%														8.00%
Debt principal amount																			38,301		38,301																					38,301					38,301		38,301
Convertible notes payable																			151,052		246,819																	$ 49,819				151,052					151,052		246,819			$ 49,819
Debt maturity date																																						Feb. 13, 2019
Debt instrument convertible debt percentage																																						24.00%														24.00%
Conversion percentage																																						60.00%
Trading days | d																																						25
Convertible Notes Payable [Member] | Convertible Debenture [Member] | Restricted Stock [Member]
Debt conversion, converted instrument, shares issued | shares																											52,244,433
Debt principal amount																											$ 15,000
Number of shares issued for conversion of debt																											37,011
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member]
Repayments of convertible debt																										$ 75,900
Conversion percentage																										50.00%
Note Payable One [Member]
Interest expense, debt																																										4,914		4,368			9,635		8,564
Note Payable One [Member] | Promissory Note [Member]
Notes payable																			14,400																							14,400					$ 14,400			$ 12,000	12,000
Debt instrument, unamortized discount net issuance costs																																																		2,400	2,000
Debt conversion, converted instrument, shares issued | shares																																															5,000,000
Debt instrument fair value																			3,000																							3,000					$ 3,000
Outstanding notes payable																			0		14,400																					0					0		14,400
Note Payable One [Member] | Director [Member]
Notes payable																																																																																						$ 200,000
Debt instrument, interest rate, stated percentage																																																																																							12.00%	10.00%
Accrued interest																																															169,190		159,555
Note Payable Two [Member]
Notes payable																			1,382,898		1,385,163																					1,382,898					1,382,898		1,385,163
Debt instrument, unamortized discount net issuance costs																			9,972		8,921																					9,972					9,972		8,921
Note Payable Two [Member] | UniversityCentreWestLtdMember
Debt instrument rent expenses																																																																																	$ 55,410
Note Payable Two [Member] | Related Party [Member]
Notes payable																																																																												$ 50,000	$ 75,000
Debt instrument, interest rate, stated percentage																																																																												2.00%	2.00%
Accrued interest																																															56,034		49,967
Repayments of notes payable																																					$ 25,000
Debt principal amount																			50,000		50,000																					50,000					50,000		50,000
Common stock, shares, issued | shares																																					5,000,000
Note Payable Two [Member] | Related Party One [Member]
Accrued interest																																															49,233		43,166
Debt principal amount																			50,000		50,000																					50,000					50,000		50,000
Note Payable Two [Member] | Unrelated Third Party [Member]
Notes payable																																																																		$ 180,250
Debt instrument, interest rate, stated percentage																																																																		2.50%
Note Payable Two [Member] | NonRelatedPartyFiveMember
Notes payable									$ 200,000	$ 12,500																															200,000
Debt instrument, interest rate, stated percentage										10.00%																																																										15.00%
Accrued interest																																															3,844		3,212
Debt issuance costs, gross									5,500																																5,500
Note Payable Two [Member] | Non Related Party Two [Member]
Debt discount																			1,473		4,421																					1,473					1,473		4,421											$ 3,945
Accrued interest																																																		282,983
Debt instrument, unamortized discount net issuance costs																					3,616																												3,616	$ 329
Common stock, shares, issued | shares																																																												10,000,000
Amortization of debt discount																			2,948																														1,474
Note Payable Two [Member] | Non Related Party Two [Member] | Subsequent Event [Member]
Debt discount																																																						$ 5,895
Notes payable																																																						$ 333,543
Common stock, shares, issued | shares																																																						20,000,000
Note Payable Two [Member] | Non Related Party Nine [Member]
Debt discount																					12,149	$ 10,000	$ 12,381																	$ 12,381				12,381				12,381	12,149
Notes payable																					60,000																												60,000
Debt instrument, unamortized discount net issuance costs																			0				8,254										10,000							8,254		0		8,254			0	8,254											$ 10,000
Non-payment penalty charges																			148,225																							148,225					148,225
Common stock, shares, issued | shares																						10,000,000
Common stock issued value																						$ 4,000
Long-term debt, maturities																					$ 76,076																												$ 76,076
Interest payable																			16,700																							16,700					16,700
Debt instrument convertible debt percentage																					2.00%																												2.00%
Note Payable Two [Member] | Non Related Party Ten [Member]
Debt discount																					$ 0																						$ 20,000						$ 0
Notes payable																					120,000																						50,000						120,000
Debt instrument, unamortized discount net issuance costs																																											120,000
Common stock, shares, issued | shares																																																		1,500,000
Common stock issued value																																																		$ 2,250
Note Payable Two [Member] | Non Related Party Eleven [Member]
Debt discount																																											20,000
Notes payable																																											50,000																					18,000
Debt instrument, unamortized discount net issuance costs																																											$ 120,000																					$ 3,000
Common stock, shares, issued | shares																																											125,000,000
Common stock issued value																																											$ 87,500
Note Payable Two [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges													$ 100,000
Note Payable Two [Member] | Southridge Partners, LLP [Member]
Notes payable																																																																																$ 281,772
Noncash transaction, value consideration received													281,772
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Two [Member]
Notes payable																			333,543		333,543																					333,543					333,543		333,543
Accrued interest																																															65,597		25,127
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Four [Member]
Accrued interest																																															45,533		39,466
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member]
Notes payable																			74,264		92,728																					74,264					74,264		92,728
Repayments of notes payable																																															18,464		42,698	$ 34,976
Cash settlement																														20,927	$ 20,927
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member] | Subsequent Event [Member]
Outstanding notes payable															33,874
Repayments of notes payable		5,000
Repayments of lines of credit		$ 2,000
Cash settlement															$ 130,401
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Nine [Member]
Common stock, shares, issued | shares																																																		10,000,000
Common stock issued value																																																		$ 3,000
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Eleven [Member]
Accrued interest																																															2,000		2,000
Repayments of notes payable																																															18,000		18,000
Common stock, shares, issued | shares																																																																7,000,000
Common stock issued value																																																																$ 5,600
Note Payable Two [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Notes payable																																																																																		$ 50,000		$ 50,000	$ 350,000
Repayments of lines of credit																																													$ 25,000
Debt principal amount																																																																																			$ 175,000
Non-payment penalty charges																																																																																			$ 25,000
Sale of stock, number of shares | shares																																													142,858
Note Payable Two [Member] | Promissory Note [Member]
Notes payable																																																																														$ 10,000
Debt instrument, interest rate, stated percentage																																																																														10.00%
Debt instrument accrued interest																																															4,258		3,755
Note Payable Two [Member] | Promissory Note [Member] | Unrelated Third Party [Member]
Notes payable																																																																										$ 150,000
Debt instrument, interest rate, stated percentage																																																																										2.50%
Note Payable Two [Member] | Promissory Note [Member] | NonRelatedPartyOneMember
Debt discount																																																																										$ 2,765
Notes payable																																																												$ 282,983
Debt instrument, interest rate, stated percentage																																																												2.00%
Repayments of notes payable							$ 220,506
Common stock, shares, issued | shares							5,000,000																						5,000,000																																													2,000,000
Common stock issued value							$ 5,500																						$ 5,500
Amortization of debt discount																																																		2,765
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Three [Member]
Notes payable																			15,000		15,000					$ 60,000																15,000					15,000		15,000																								$ 75,000
Debt instrument, interest rate, stated percentage																																																																									10.00%
Accrued interest																																															1,371		1,371
Debt instrument accrued interest																										15,900
Long-term debt, maturities																										$ 15,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Four [Member]
Notes payable																																																																								$ 50,000
Debt instrument, interest rate, stated percentage																																																																								2.00%
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Seven [Member]
Notes payable									50,000										50,000		50,000																				$ 50,000	50,000					50,000		50,000
Amortization of debt discount									$ 10,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member]
Notes payable																			30,000		30,000														$ 36,000							30,000					30,000		30,000
Accrued interest																																															1,500		4,500
Debt instrument, unamortized discount net issuance costs																						6,000					6,000								6,000
Repayments of notes payable																						$ 5,000					$ 7,000								$ 1,500												3,000
Amortization of debt discount																																																	7,500	4,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member] | Subsequent Event [Member]
Notes payable	$ 30,000													$ 30,000																																$ 30,000										33,000
Debt instrument, interest rate, stated percentage	12.00%													12.00%																																12.00%
Debt instrument, unamortized discount net issuance costs																																																								$ 3,000
Debt instrument convertible price per share | $ / shares	$ 0.01													$ 0.01																																$ 0.01
Repayments of notes payable														$ 1,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Nine [Member]
Debt discount																																																																	3,200
Notes payable																																																			$ 60,000														50,000
Debt instrument, unamortized discount net issuance costs																																																																	$ 10,000
Common stock, shares, issued | shares																																																															1,000,000		5,000,000
Common stock issued value																																																															$ 1,700
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member]
Debt discount																			14,000																							14,000					14,000																	5,600
Notes payable																			70,000																							70,000					70,000																	120,000
Debt instrument, unamortized discount net issuance costs																																																																$ 20,000
Cash settlement																			$ 37,500																							$ 37,500					$ 37,500
Common stock, shares, issued | shares																			46,000,000																							46,000,000					46,000,000																	10,000,000
Common stock issued value																			$ 32,200																							$ 32,200					$ 32,200
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eleven [Member]
Common stock, shares, issued | shares																																																																5,000,000
Common stock issued value																																																																$ 2,900
Note Payable Two [Member] | Promissory Note Two [Member]
Notes payable					$ 101,818																																																														$ 201,818
Debt instrument, interest rate, stated percentage																																																																			12.00%
Accrued interest																																															35,403		50,971
Outstanding notes payable																			91,156																							91,156					91,156
Debt instrument convertible price per share | $ / shares																																																																						$ 0.008
Repayments of notes payable											$ 6,365
Repayments of lines of credit																																															37,500		13,500
Debt settlement																																											$ 88,500
Gain loss on extinguishment of debt																																															15,500	18,841
Note Payable Two [Member] | Promissory Note Two [Member] | Scheduled Payments Through May 1, 2020 [Member]
Accrued interest					21,023
Repayments of lines of credit					$ 104,000
Note Payable Two [Member] | Promissory Note Two [Member] | Settlement [Member]
Accrued interest																																															35,403
Note Payable Two [Member] | Reverse Stock Split [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges													350,000
Sale of stock, number of shares | shares																																													5,714,326
Cash settlement													450,000
Debt default, amount													$ 100,000
Note Payable Two [Member] | Note Holder [Member] | Non Related Party Nine [Member]
Debt discount																																	8,678
Debt instrument, unamortized discount net issuance costs																								10,000									18,678																												$ 10,000
Debt default, amount																								$ 2,381
Common stock, shares, issued | shares																								5,000,000
Common stock issued value																																	$ 60,000
Note Payable Two [Member] | Director [Member] | Promissory Note Two [Member]
Notes payable																			128,656		160,633																					128,656					128,656		160,633	192,974																								$ 200,000
Debt instrument, interest rate, stated percentage																																																																										12.00%
Accrued interest																																																	37,500	$ 40,033
Repayments of notes payable										$ 8,844
Note Payable Two [Member] | Former Director [Member] | Promissory Note Two [Member]
Notes payable																																																																										$ 100,000
Note Payable Two [Member] | Two Unrelated Parties [Member] | Settlement Agreement [Member]
Repayments of notes payable																														130,401
Repayments of lines of credit																														$ 40,000
Convertible Notes Payable Three of the Notes [Member] | Unrelated Third Parties [Member]
Repayments of convertible debt																					$ 13,500
Convertible Notes Payable Six of the Notes [Member] | Unrelated Third Parties [Member]
Debt conversion, converted instrument, shares issued | shares																					800,000,000
Repayments of convertible debt																					$ 87,100
Convertible Notes Payable One [Member]
Outstanding notes payable																			852,216																							852,216					852,216
Amortization of debt discount																																															3,084
Convertible Notes Payable One [Member] | Convertible Debtentures [Member]
Debt instrument, interest rate, stated percentage								8.00%																										8.00%
Debt principal amount																			220,000		220,000																					220,000					220,000		220,000
Convertible notes payable								$ 200,000											864,535		1,412,175													$ 200,000								864,535					864,535		1,412,175
Debt maturity date																																		Feb. 28, 2019
Debt instrument convertible debt percentage								24.00%																										24.00%
Conversion percentage																																		60.00%
Trading days | d																																		25
Derivative loss								$ 1,646,242																										$ 1,646,242
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																														8.00%	8.00%
Debt principal amount																					66,000																												66,000
Convertible notes payable																					417,576									$ 60,000	$ 60,000																		417,576
Debt instrument convertible debt percentage																														24.00%	24.00%
Conversion percentage																															60.00%
Trading days | d																															25
Derivative loss																														$ 48,418	$ 48,418
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt principal amount																			66,000																							66,000					66,000
Convertible notes payable																			255,959																							255,959					255,959
Convertible Notes Payable One [Member] | Back and End Note [Member] | Unrelated Third Party [Member]
Convertible notes payable																														$ 60,000	$ 60,000
Convertible Loans One [Member]
Debt instrument, unamortized discount net issuance costs																			0		22,344																					0					0		22,344
Convertible notes payable																			3,613,041		5,814,047																					3,613,041					3,613,041		5,814,047
Convertible Notes Payable Two [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																																8.00%
Debt principal amount																			60,000		60,000																					60,000					60,000		60,000
Convertible notes payable																			226,953		369,372											$ 60,000										226,953					226,953		369,372
Debt maturity date																																May 31, 2019
Debt instrument convertible debt percentage																																24.00%
Conversion percentage																																60.00%
Trading days | d																																25
Derivative loss																																$ 59,257
Convertible Notes Payable Three [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage																												8.00%
Debt principal amount																			31,500		31,500																					31,500					31,500		31,500
Convertible notes payable																			113,351		183,565							$ 31,500														113,351					113,351		183,565
Debt maturity date																												Aug. 31, 2019
Debt instrument convertible debt percentage																												24.00%
Conversion percentage																												60.00%
Trading days | d																												25
Derivative loss																												$ 23,794
Convertible Notes Payable Four [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate, stated percentage							8.00%																						8.00%
Convertible notes payable							$ 50,000												156,166		180,176								$ 50,000													156,166					156,166		180,176
Debt maturity date																													Jul. 31, 2019
Debt instrument convertible debt percentage							24.00%																						24.00%
Conversion percentage																													55.00%
Trading days | d																													15
Derivative loss							$ 46,734																						$ 46,734
Convertible Notes Payable Five [Member] | Convertible Debtentures [Member] | Non Related Party Twenty Two[Member]
Debt instrument, interest rate, stated percentage																												8.00%
Convertible notes payable																			61,337		70,635							$ 20,000														61,337					61,337		70,635
Debt maturity date																												Aug. 31, 2019
Debt instrument convertible debt percentage																												24.00%
Conversion percentage																												55.00%
Trading days | d																												15
Derivative loss																												$ 17,829
Convertible Notes Payable [Member]
Convertible notes payable																			199,238		253,000																					199,238					199,238		253,000
Convertible Notes Payable [Member] | Six Tranches [Member]
Convertible notes payable																			391,748																							391,748					391,748
Convertible Promissory Note [Member]
Debt discount																			22,344																							22,344					22,344
Debt instrument, unamortized discount net issuance costs																							40,000																	$ 40,000				40,000				40,000
Debt conversion, converted instrument, shares issued | shares																																							500,000,000	750,000,000
Repayments of notes payable																									27,000
Debt principal amount																			116,748																							116,748					116,748
Amortization of debt discount																							4,688																								22,344	0
Convertible notes payable																			306,462				240,000																	$ 240,000		306,462		240,000			306,462	240,000
Interest payable																									11,412
Debt conversion principle amount																																							$ 175,000	100,000
Number of shares issued for conversion of debt																																							$ 425,000	275,000
Derivative loss																							$ 240,000		$ 610,210															$ 240,000				$ 240,000				$ 240,000
Debt instrument conversion terms																							The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.		The note is due two years from the execution and funding of the note per tranche. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.
Stock issued during period, restricted stock | shares																							16,000,000
Convertible Promissory Note [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares																									$ 0.0005
Debt principal amount																									$ 1,000,000
Convertible Promissory Note [Member] | Unrelated Third Party [Member]
Debt discount																			0		22,344																					0					0		22,344
Convertible notes payable																			630,000		$ 800,000																					630,000					630,000		$ 800,000
Convertible Promissory Note [Member] | Note Agreement [Member]
Convertible notes payable																			$ 83,917																							$ 83,917					$ 83,917
Debt maturity date																																															Apr. 30, 2023

Debts - Schedule of Future Mini

Debts - Schedule of Future Minimum Principal Payment (Details)	Jun. 30, 2020USD ($)
Debt Disclosure [Abstract]
2021	$ 10,726
2022	56,290
2023	3,283
2024	3,408
2025	3,538
Thereafter	137,650
Total	$ 214,895

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Feb. 18, 2020	Jan. 21, 2020	Oct. 30, 2017	Jun. 30, 2020	Mar. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Jun. 30, 2019	Apr. 30, 2019	Jun. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Mar. 07, 2018	Nov. 30, 2017	Apr. 30, 2016
Common stock, shares authorized				8,000,000,000							8,000,000,000		8,000,000,000		8,000,000,000	2,000,000,000
Preferred stock, shares authorized			20,000,000	20,000,000							20,000,000		20,000,000		20,000,000
Available for distribution, cash per share			$ 0.133
Number of shares issued for conversion of debt, shares	250,000,000	250,000,000
Notes payable				$ 6,347,950							$ 6,347,950		$ 6,347,950		$ 8,260,866
Common stock per share value				$ 0.001							$ 0.001		$ 0.001		$ 0.001
Stock issued during the period for services												$ 30,000		$ 30,000
Restricted Stock [Member]
Equity compensation charge											$ 1,000		$ 8,500		$ 21,500
Restricted Stock [Member] | Consultant [Member]
Stock issued during the period for services, shares								15,000,000	120,000,000
Stock issued during the period for services								$ 6,000	$ 24,000
Consultant Agreement [Member] | Restricted Stock [Member]
Stock issued during the period for services, shares										100,000,000
Common stock per share value										$ 0.0012
Non Related Party Ten [Member]
Notes payable				$ 77,000							77,000		77,000
Debt discount				7,000							7,000		7,000
Three note holder [Member] | Restricted Stock [Member]
Equity compensation charge								$ 120,000			0	$ 26,500	0	$ 56,500
Note Payable Two [Member]
Notes payable				1,382,898							1,382,898		1,382,898		1,385,163
Debt instrument, unamortized discount net issuance costs				$ 9,972							9,972		9,972		8,921
Note Payable Two [Member] | Non Related Party Ten [Member]
Notes payable					$ 50,000										120,000
Debt instrument, unamortized discount net issuance costs					120,000
Debt discount					$ 20,000										$ 0
Number of shares issued for settlement of debt					125,000,000
Shares issued for settlement of debt amount					$ 87,500
Other expense, debt					$ 37,500
Notes Payable [Member]
Number of shares issued for conversion of debt, shares						500,000,000	500,000,000
Debt instrument, face amount						$ 175,000	$ 175,000
Notes Payable [Member] | Maximum [Member]
Debt instrument, face amount						$ 1,000,000	$ 1,000,000
Promissory Note [Member] | Debt Modification and Penalty [Member]
Stock issuance during period, shares				5,000,000	121,000,000		121,000,000
Shares issued for settlement of debt amount				$ 14,400
Stock issuance during period, value				3,000	$ 77,200		$ 77,200
Promissory Note [Member] | Note Payable Two [Member]
Notes payable																		$ 10,000
Promissory Note [Member] | Note Payable Two [Member] | Non Related Party Ten [Member]
Notes payable				70,000							70,000		70,000				$ 120,000
Debt instrument, unamortized discount net issuance costs																	20,000
Debt discount				$ 14,000							$ 14,000		$ 14,000				$ 5,600
Series A Preferred Stock [Member]
Stock issuance during period, shares			3,000,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Feb. 18, 2020	Jan. 21, 2020
Equity [Abstract]
Number of shares converted	250,000,000	250,000,000
Fair value of debt converted	$ 275,000	$ 150,000

Stock Warrants (Details Narrati

Stock Warrants (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended	12 Months Ended
	Dec. 31, 2019	Feb. 28, 2019	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2017	Apr. 04, 2016	Mar. 03, 2016	Apr. 30, 2014
Notes Payable	$ 8,260,866		$ 6,347,950	$ 8,260,866
Number of warrants to purchase common stock									100,000
Warrants, exercise price per share									$ 0.025
Fair value of warrants	7,370	$ 8,147			$ 0
Warrants, expiration date									Apr. 9, 2019
Three Convertible Notes Payable [Member]
Notes Payable	$ 22,000	$ 70,000		22,000
Warrants, exercise price per share		$ 0.001
Three Year Warrant [Member]
Notes Payable						$ 80,000
Warrants, term						3 years	3 years
Number of warrants to purchase common stock						6,000,000	4,000,000
Warrants, exercise price per share						$ 0.005	$ 0.05
Fair value of warrants			0	539
Warrants, expiration date						Mar. 30, 2020	Apr. 4, 2019
Five Year Warrant [Member]
Warrants, term								5 years
Number of warrants to purchase common stock								2,500,000
Warrants, exercise price per share								$ 0.03
Fair value of warrants			517	$ 872
Warrants, expiration date								Mar. 3, 2021
Warrants [Member]
Warrants, intrinsic value			$ 0
Stock price			$ 0.0007

Stock Warrants - Schedule of Wa

Stock Warrants - Schedule of Warrants Issued (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Number of Warrants	44,000,000	110,000,000
Fair Value of Warrants	$ 7,370	$ 8,147	$ 0
Month of Expiration	August, 2020	August, 2019

Stock Warrants - Summary of War

Stock Warrants - Summary of Warrants Outstanding (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0028
Weighted Average Exercise Price, Warrants, Ending	$ 0.0026	$ 0.0028
Warrants [Member]
Number of warrants outstanding, Beginning	52,500,000	12,600,000
Number of warrants, Exercised
Number of warrants, Issued		154,000,000
Number of warrants, Expired	(6,000,000)	(114,100,000)
Number of warrants outstanding, Ending	46,500,000	52,500,000
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0028	$ 0.026
Weighted Average Exercise Price, Warrants, Exercised
Weighted Average Exercise Price, Warrants, Issued		0.001
Weighted Average Exercise Price, Warrants, Expired	0.005	0.0027
Weighted Average Exercise Price, Warrants, Ending	$ 0.0026	$ 0.0028

Stock Warrants - Summary of Fix

Stock Warrants - Summary of Fixed Price Warrants Outstanding (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Apr. 30, 2014
Exercise Price			$ 0.025
Weighted Average Exercise Price	$ 0.0026	$ 0.0028
Maximum [Member]
Exercise Price	0.001	0.001
Minimum [Member]
Exercise Price	$ 0.03	$ 0.03
Weighted Average Number Outstanding	46,500,000	10,187,671
Weighted Average Contractual Life	2 months 1 day	7 months 13 days

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued consulting fees	$ 161,550	$ 161,550
Accrued settlement expenses	35,000	35,000
Accrued payroll taxes	191,817	167,906
Accrued interest	279,975	231,186
Accrued others	14,013	16,905
Total	$ 682,355	$ 612,547

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Future reserve for purchases	$ 0	$ 23,948
Total valuation allowance for prepaid	$ 224,859	$ 224,859

Prepaid Expenses - Schedule of

Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Supplier advances for future purchases	$ 235,474	$ 224,859
Reserve for supplier advances	(224,859)	(224,859)
Net supplier advances	10,615
Prepaid professional fees	4,650	8,650
Deferred stock compensation		8,500
Total	$ 15,265	$ 17,150

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

Feb. 15, 2019

Aug. 01, 2017

Apr. 12, 2017

Aug. 26, 2016

Feb. 28, 2016

Oct. 31, 2015

Jul. 31, 2015

Jun. 30, 2020

Jun. 30, 2019

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2016

Operating lease term

3 years

Operating lease due

$ 3,200

Lease expiration date

Feb. 28, 2019

Lease, description

The lease was month-to-month and terminated in May 2020

Common stock shares issued

6,627,746,111

5,876,746,111

1,000,000

Note issued

$ 87,500

$ 32,400

Shares issued, price per share

$ 0.18

$ 0.18

Accrued liabilities for commissions, expense and taxes

$ 142,500

$ 142,500

Equity compensation charges

$ 31,750

Accrued expenses

$ 19,150

$ 19,150

Share based compensation, shares not yet issued

1,500,000

Long-term debt

$ 214,895

Loss contingency, allegations

The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company's issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company's stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.

Accrued interest

$ 32,676

Consulting Services Agreement [Member] | Restricted Stock [Member]

Consulting service term

5 years

Common stock shares issued

500,000

Debt instrument, interest rate

8.00%

Note issued

$ 50,000

Consultant Agreement [Member]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted

2,500,000

Consultant Agreement [Member] | Common Stock [Member]

Debt instrument periodic payment

$ 3,000

Recepto Pharm Leases [Member]

Operating lease due

$ 6,900

Lease, description

ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year.

Paul Reid et al [Member]

Loss contingency, damages sought, value

$ 315,000

Get Credit Healthy, Inc. and Rik Deitsch,[Member]

Loss contingency, damages sought, value

$ 100,000

Long-term debt

$ 101,818

Long-term debt, accrued interest

$ 21,023

Payments for legal settlements

$ 104,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Lease Cost and Balance Sheet Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 44,510
Short-term lease cost	18,698
Total lease cost	63,208
Operating ROU Assets	168,234	$ 207,530
Operating lease obligations, current portion	77,945	73,278
Operating lease obligations, non-current portion	103,432	$ 143,322
Total operating lease obligations	$ 181,377
Weighted average remaining lease term (in years) - operating leases	2 years 2 months 1 day
Weighted average discount rate-operating leases	8.00%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 40,437

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Payments Under Lease Agreements (Details) - USD ($)	Jun. 30, 2020	Feb. 28, 2016
Total future lease payments		$ 3,200
Total	$ 181,377
Lease Agreements [Member]
2020 (Remaining six months)	44,687
2021	91,379
2022	62,274
Total future lease payments	198,340
Less imputed interest	16,963
Total	$ 181,377

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2021	May 20, 2021	Mar. 10, 2021	Dec. 31, 2020	Nov. 30, 2020	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Sep. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Jan. 31, 2019	Jun. 30, 2018	May 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jul. 31, 2021	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2018	Apr. 30, 2014
Warrants, exercise price per share																													$ 0.025
Debt instrument accrued interest																							$ 12,150
Loss on settlement of debt																							(22,000)	57,253
Repayments of convertible debt																								$ 10,000
Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount																				$ 553,301			$ 553,301					$ 12,000
Minimum [Member]
Warrants, exercise price per share																				$ 0.03			$ 0.03			$ 0.03
Consultant Agreement [Member] | Restricted Stock [Member]
Stock issued during period, shares, issued for services																		100,000,000
Convertible Notes Payable [Member]
Debt instrument, original discount																				$ 0			$ 0			$ 22,344	$ 5,000
Warrants, exercise price per share																										$ 0.001
Number of warrants																										$ 8,147
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member]
Repayments of convertible debt																	$ 75,900
Convertible Notes Payable [Member] | Minimum [Member]
Debt conversion price																				$ 0.00025			$ 0.00025			$ 0.00010
Convertible Notes Payable [Member] | Note Agreement [Member]
Debt instrument, face amount																				$ 116,748			$ 116,748				$ 1,000,000
Proceeds from loan																							87,345
Convertible Notes Payable [Member] | Warrants [Member]
Warrants, exercise price per share																										$ 0.001
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, original discount																				9,250			9,250
Convertible Notes Payable [Member] | Third Party [Member] | Restated [Member]
Debt instrument, face amount																	$ 75,900
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Debt instrument, face amount																				$ 12,629			$ 12,629			$ 12,629
Debt instrument, interest rate																			8.00%
Debt instrument, expiration or maturity date																			May 4, 2018
Subsequent Event [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount																$ 166,926
Debt instrument, due date																2021-01
Debt instrument accrued interest										$ 23,258
Debt instrument, interest rate																2.00%
Number of shares issued										29,072,500
Number of shares issued, value										$ 343,056
Other income										319,798
Restated debt balance										183,619
Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount								$ 8,500
Debt instrument fair value								$ 15,200
Debt instrument accrued interest													$ 166,168
Number of shares issued								2,000,000
Number of shares issued, value								$ 4,000
Repayment of debt								4,500
Loss on settlement of debt								11,200
Subsequent Event [Member] | Restated [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount										166,926						$ 148,225
Debt instrument, original discount										$ 16,693
Debt instrument, due date										2021-08
Debt instrument accrued interest																$ 18,701
Subsequent Event [Member] | Unrelated Third Parties [Member] | Common Stock Issued for Default Payments [Member]
Debt instrument, face amount				$ 26,950
Debt instrument, original discount				$ 2,450
Debt conversion price				$ 0.01
Debt instrument, expiration or maturity date				Mar. 10, 2022
Subsequent Event [Member] | Unrelated Third Parties [Member] | Convertible Note [Member]
Debt instrument, face amount			$ 145,200
Debt instrument, original discount			$ 13,200
Debt conversion price			$ 0.01
Debt instrument, expiration or maturity date			May 20, 2022
Subsequent Event [Member] | Consultant Agreement [Member]
Stock issued during period, shares, issued for services	30,000,000
Stock based compensation description	5,000,000 of the shares were issued upon execution of the agreement and 5,000,000 shares will be issued every 30 days through November 2021. The compensation charge will be amortized over the term of the agreement.
Subsequent Event [Member] | Warrants [Member]
Debt instrument, original discount						$ 7,500						$ 7,500
Warrants, exercise price per share						$ 0.002						$ 0.002
Number of warrants, granted						71,875,000
Number of warrants						$ 30,417						$ 30,417
Subsequent Event [Member] | Note Holder [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount									$ 11,000				$ 22,000	$ 22,000
Stock issued during period, restricted stock													107,817,770	107,133,333
Debt instrument accrued interest													$ 10,345	$ 10,140
Number of shares issued									11,000,000
Number of shares issued, value									$ 104,500
Remaining debt sold													$ 467,319
Repayment of debt									6,000
Loss on settlement of debt									98,500
Subsequent Event [Member] | Note Holder [Member] | Common Stock Issued for Default Payments [Member] | Restricted Stock [Member]
Stock issued during period, restricted stock											25,000,000		1,500,000	10,000,000		1,000,000
Stock issued during period, restricted stock value											$ 107,500		$ 900	$ 6,000		$ 700
Repayments of convertible debt											$ 166,926		84,000	$ 333,543		22,000
Subsequent Event [Member] | Note Holder [Member] | Repayments of Debt in Cash [Member] | Settlement of Convertible Promissory Notes [Member]
Repayment of debt									$ 5,000
Subsequent Event [Member] | Unrelated Third Party [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument accrued interest													250,000
Subsequent Event [Member] | Convertible Notes Payable [Member] | Minimum [Member]
Debt conversion price	$ 0.0008	$ 0.0008					$ 0.0008		$ 0.0003													$ 0.0008
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount	$ 864,225	$ 864,225					$ 864,225		$ 717,667													$ 864,225			$ 16,100
Debt instrument, original discount	$ 112,725	$ 112,725					$ 112,725		$ 93,609													$ 112,725			$ 2,100
Debt conversion price	$ 0.002	$ 0.002					$ 0.002		$ 0.002													$ 0.002			$ 0.002
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Agreement [Member]
Proceeds from loan		$ 87,345
Stock issued during period, restricted stock																						240,350,000
Stock issued during period, restricted stock value																						$ 120,175
Debt instrument fair value	$ 2,344,399	2,344,399					$ 2,344,399															2,344,399
Subsequent Event [Member] | Convertible Notes Payable [Member] | Warrants [Member]
Debt instrument, original discount													$ 29,481
Warrants, exercise price per share													$ 0.001
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount													$ 16,500		$ 38,500	20,900
Debt instrument, original discount													$ 1,650		$ 7,550	$ 1,900
Debt instrument, due date													2021-04		2021-02
Repayments of convertible debt							19,500	$ 19,500
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder [Member]
Debt instrument, face amount	83,917	83,917				20,000	83,917					$ 20,000										$ 83,917
Debt instrument, original discount													$ 9,200
Debt instrument, due date																2021-01						2023-04
Debt conversion price													$ 0.0005			$ 0.00052
Stock issued during period, restricted stock																						240,350,000
Stock issued during period, restricted stock value																						$ 120,175
Debt instrument fair value	$ 2,344,399	$ 2,344,399					$ 2,344,399															$ 2,344,399
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties One [Member]
Debt instrument, face amount															$ 22,000
Debt instrument, original discount															$ 2,000
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder One [Member]
Debt instrument, due date															2021-08
Debt conversion price															$ 0.0005
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties Two [Member]
Debt instrument, face amount															$ 5,500
Debt instrument, original discount															$ 500
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder Two [Member]
Debt instrument, due date															2021-02
Debt conversion price															$ 0.0005
Subsequent Event [Member] | Convertible Notes Payable [Member] | Third Party [Member]
Debt instrument, face amount					$ 55,900
Debt instrument, due date					2021-01
Stock issued during period, restricted stock												100,000,000
Stock issued during period, restricted stock value												$ 20,000
Debt instrument fair value						140,000						140,000
Subsequent Event [Member] | Convertible Notes Payable [Member] | Three Unrelated Third Parties [Member]
Debt instrument, face amount						208,800						208,800
Debt instrument, original discount						$ 19,800						$ 19,800
Debt conversion price						$ 0.0005						$ 0.0005
Subsequent Event [Member] | Convertible Notes Payable [Member] | Three Unrelated Third Parties [Member] | Minimum [Member]
Debt conversion price						$ 0.00022						$ 0.00022
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount						$ 139,150						$ 139,150
Debt instrument, original discount						$ 12,650						$ 12,650
Debt conversion price						$ 0.00055						$ 0.00055
Subsequent Event [Member] | Two Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount					$ 57,500	$ 57,500						$ 57,500
Debt instrument, original discount					$ 7,500	$ 7,500						$ 7,500
Debt conversion price					$ 0.0008	$ 0.0008						$ 0.0008

Subsequent Events - Summary of

Subsequent Events - Summary of Warrants Issuance (Details) - USD ($)	1 Months Ended				12 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2018
Number of Warrants			44,000,000	110,000,000
Fair Value of Warrants			$ 7,370	$ 8,147	$ 0
Month of Expiration			August, 2020	August, 2019
Subsequent Event [Member] | Warrants [Member]
Number of Warrants	39,930,000	92,100,000
Fair Value of Warrants	$ 8,633	$ 20,848
Month of Expiration	October, 2022	August, 2021

Subsequent Events - Schedule of

Subsequent Events - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020
Number of shares converted								250,000,000	250,000,000
Fair value of debt converted								$ 275,000	$ 150,000
Subsequent Event [Member] | Note Holder [Member]
Number of shares converted	2,500,000	5,700,000	27,070,000	67,380,000	137,700,000	107,817,770	107,133,333
Fair value of debt converted	$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930	$ 64,691	$ 171,413